WO2013145869A1 - Absorbent article - Google Patents

Abstract

Provided is an absorbent article (1) that minimizes contact of a section of the side surfaces (41, 41) of an absorbent body (4) with the inner thigh of a wearer when wing sections (6, 6) have been folded and attached to underwear, and that minimizes the occurrence of large twists in the aforementioned section of the side surfaces (41, 41) of the absorbent body (4). The present invention is an absorbent article (1) comprising: a main body section (10) provided with a top sheet (2), a back sheet (3), and an absorbent body (4); and wing sections (6, 6) that are arranged on both sides of the main body section (10). The main body section (10) also comprises a bend-inhibiting sheet (5) that is provided between the absorbent body (4) and the back sheet (3). The edges (51, 51) on both sides of the bend-inhibiting sheet (5) in the width direction are positioned farther outward in the width direction than the side surfaces (41, 41) of the absorbent body. The bend-inhibiting sheet (5) imparts rigidity to the absorbent article (1) such that the absorbent article (1) is harder to bend in the area in which the bend-inhibiting sheet (5) is provided than in the area in which the bend-inhibiting sheet (5) is not provided.

Description

Absorbent articles

The present invention relates to absorbent articles such as sanitary napkins, panty liners, incontinence pads, incontinence liners and the like.

A sanitary napkin having a pair of flaps extending laterally outward beyond the longitudinal side edge of the main part is known in the prior art (e.g., U.S. Pat. No. 5,958,015). When the sanitary napkin is worn, the flaps are folded under the wearer's underwear. In this sanitary napkin, when the width of the crotch of the wearer's underwear is smaller than the width of the main portion, the flap is folded along the longitudinal portion of the inner main portion of the proximal end. If the crotch width of the wearer's underwear is wider than the width of the main part, the flap is folded along the hinge of the main part.

Japanese Patent Publication No. 2003-510164

However, in the conventional absorbent article as described in Patent Document 1, when the width of the crotch area of the wearer's underwear is narrower than the width of the absorbent provided in the absorbent article, the wing portion is the absorbent May be broken along the sides of the In this case, the side portion of the absorber may hit the wearer's inner crotch, causing a strong discomfort in the wearer's inner crotch. In addition, large deflection may occur in the side portion of the absorber, and the body fluid of the wearer may leak in the width direction of the absorbent article.

According to the present invention, even when the width of the crotch area of the wearer's underwear is narrower than the width of the absorbent provided in the absorbent article, when the wing is folded and the absorbent article is attached to the underwear, An object of the present invention is to provide an absorbent article which can suppress that the side portion of the absorber hits the inner crotch of the wearer and can suppress the occurrence of large deflection in the side portion of the absorber.

The present invention adopts the following configuration in order to solve the above-mentioned problems.
That is, according to the present invention, a liquid-permeable top sheet provided on the skin side, having a longitudinal direction and a width direction, a liquid-impermeable back sheet provided on the clothing side, the top sheet, and the back sheet A main body portion provided with a liquid-retaining absorber including a side surface extending in the longitudinal direction on both sides in the width direction, and both sides of the main body portion extending in the width direction from both side edges of the main body portion An absorbent article including a wing portion disposed in the body, wherein the main body portion is provided between the absorber and the back sheet, and further includes a bending suppression sheet including longitudinally extending edges on both sides in the width direction The edge on both sides in the width direction of the anti-folding sheet is located outside the side surface of the absorber in the width direction, and the area where the anti-folding sheet is provided is the area where the anti-folding sheet is not provided So that the absorbent article is harder to bend than , Folding suppression sheet imparts rigidity to the absorbent article.

According to the present invention, even when the width of the crotch area of the wearer's underwear is narrower than the width of the absorbent provided in the absorbent article, when the wing is folded and attached to the underwear, the absorbent While suppressing that the part of a side of a part hits a wearer's inner crotch, it can suppress that a big distortion arises in the part of the side of an absorber.

FIG. 1 is a partially broken plan view of an embodiment of the absorbent article of the present invention. FIG. 2 is a schematic cross-sectional view showing a cross section taken along line AA of FIG. FIG. 3 shows a first mountain-folded part, a second mountain-folded part, formed in the region on the outer side of both side surfaces in the width direction of the absorber in the top sheet of the main body part according to an embodiment of the present invention It is a figure for demonstrating a part and a valley fold part. FIG. 4 is a view for explaining a first mountain fold, a second mountain fold and a valley fold formed on the top sheet of the central part of the main body in the absorbent article according to one embodiment of the present invention. is there. FIG. 5 is a view for explaining an absorbent article according to an embodiment of the present invention attached to the crotch region of the undergarment. FIG. 6 is a schematic cross-sectional view showing a cross section taken along the line BB of FIG. FIG. 7 is a figure for demonstrating the manufacturing method of the absorbent article of one Embodiment of this invention. FIG. 8 is a view for explaining a recess-forming roll used for producing the absorbent article of one embodiment of the present invention. FIG. 9 is a view for explaining a region where a recess is formed by the recess forming roll in the top sheet. FIG. 10 is a view for explaining an upper stage roll of a drawing gear roll used for manufacturing an absorbent article according to an embodiment of the present invention. FIG. 11 is a view for explaining a lower roll of a drawing gear roll used for manufacturing an absorbent article according to an embodiment of the present invention. FIG. 12 is a view for explaining a top sheet sheet stretched by a stretching gear roll. FIG. 13 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin in which the top sheet contains avian C2L oil fatty acid glyceride. FIG. 14 is a photomicrograph of menstrual blood with or without a blood modifying agent. FIG. 15 is a diagram for explaining a method of measuring surface tension.

Hereinafter, the present invention will be described with reference to the drawings, but the present invention is not limited to those described in the drawings.

FIG. 1 is a partially broken plan view of an absorbent article according to an embodiment of the present invention, and FIG. 2 is a schematic cross-sectional view taken along the line AA of FIG. The absorbent article 1 has a liquid-permeable top sheet 2 provided on the skin side (skin contact side), a liquid-impermeable back sheet 3 provided on the clothing side (non-skin contact side), and a top sheet A liquid-retaining absorber 4 provided between the second sheet 2 and the back sheet 3 and a main body 10 having a bending suppression sheet 5 provided between the absorber 4 and the back sheet 3; It includes a pair of wing portions 6 provided with a top sheet 2 and a back sheet 3 disposed on both sides of the main body portion 10 so as to extend in the width direction from both side edges. The code | symbol 61 shows the root of the wing part 6 (boundary between the main-body part 10 and the wing part 6). For example, a straight line connecting two points where the width of the absorbent article 1 suddenly increases on both sides in the longitudinal direction of the wing portion 6 can be regarded as the root 61 of the wing portion 6. The surface on the opposite side of the surface on the clothing side in the wing portion 6 is configured by the top sheet 2. Adhesive portions 7 are provided on the clothes-side surfaces of the main body portion 10 and the wing portion 6 respectively. In addition, in FIG. 1, the width direction of the absorbent article 1 is the X direction, and the longitudinal direction is the Y direction. Moreover, the plane direction of the absorbent article 1 is the XY direction.

The shape of the main body portion 10 is not particularly limited as long as it is a shape that conforms to the shape of a female body and an underwear, such as a rectangular shape, an oval shape, and an hourglass shape. The longitudinal dimension in the outer shape of the main body 10 is preferably 100 to 500 mm, more preferably 150 to 350 mm. Further, the dimension in the width direction of the outer shape of the main body 10 is preferably 30 to 200 mm, more preferably 40 to 180 mm.

The top sheet 2 moves body fluid such as urine and menstrual blood discharged from the wearer to the absorber 4 in the main body portion 10. Further, in the main body portion 10, at least a part of the top sheet 2 has liquid permeability, and has a large number of openings for transmitting body fluid. On the other hand, in the wing portion 6, the top sheet 2 is suitable for the wearer to bend the wing portion 6, and has a suitable rigidity not to give the wearer discomfort after being attached to the undergarment, as described later. Apply to wing 6 together with 3.

The top sheet 2 is preferably made of a resin film. The resin film used as the top sheet 2 is made of a copolymer of an olefin and an acrylic ester, another monomer such as vinyl acetate, polyolefin, polyester, polypropylene, polyethylene, polyethylene terephthalate, polyamide, cellulose acetate or the like. The resin film used as the top sheet 2 is preferably a copolymer of an olefin and another monomer, or a polyolefin, in terms of high flexibility and low irritation to the skin.

The basis weight of the top sheet 2 is preferably 1 g / m ² or more and 40 g / m ² or less, more preferably 10 g / m ² or more and 35 g / m ² or less. Moreover, the thickness of the resin film which comprises the top sheet 2 becomes like this. Preferably it is 0.01 mm or more and 0.4 mm or less, More preferably, it is 0.1 mm or more and 0.35 mm or less. When the thickness of the resin film constituting the top sheet 2 is less than 0.01 mm, the hiding property of the top sheet 2 described later may be too small, and the thickness of the resin film constituting the top sheet 2 is 0 When it exceeds .4 mm, the rigidity of the top sheet 2 may be high, and the stimulation of the top sheet 2 to the wearer's skin may be too strong. Since the top sheet 2 has a first mountain fold portion, a second mountain fold portion and a valley fold portion described later, the apparent thickness of the top sheet 2 is greater than the thickness of the resin film constituting the top sheet 2 large. The apparent thickness of the top sheet 2 is preferably 0.01 mm or more and 1 mm or less, more preferably 0.1 mm or more and 0.5 mm or less.

The top sheet 2 has concealability in order to prevent the body fluid absorbed by the absorber 4 from being seen from the outside. The hiding property of the top sheet 2 is produced by mixing a filler such as titanium oxide into the resin. When the filler is titanium oxide, the content of titanium oxide is preferably 1% to 50%, more preferably 3% to 15%, based on the weight of the resin film. When the content of the titanium oxide is less than 1% with respect to the weight of the resin film, the effect of hiding the body fluid absorbed by the absorber 4 in the top sheet 2 may be too small. When the content of titanium oxide exceeds 50% with respect to the weight of the resin film, sheet forming of the resin containing titanium oxide may be difficult.

The top sheet 2 extends in the longitudinal direction, and extends in a direction intersecting the first mountain fold 21 and the valley fold 23 alternately arranged in the width direction, and the first mountain fold 21. And a mountain fold portion 22.

The first mountain fold 21, the second mountain fold 22 and the valley fold 23 provided in the top sheet 2 will be described in detail with reference to FIGS. 3 and 4. FIG. 3 is a first mountain-folded portion formed on the region 14 outside the side surfaces 41 in the width direction of the absorber 4 in the top sheet 2 of the main body 10 and the top sheet 2 of the wing 6 (see FIG. 1) It is a figure for demonstrating a 2nd mountain fold part and a valley fold part. FIG. 4 is a view for explaining a first mountain fold, a second mountain fold, and a valley fold formed on the central portion 12 of the top sheet 2 of the main body 10 (see FIG. 1). A first mountain fold, a second mountain fold, and a valley fold formed on the region 14 outside the both side surfaces 41 in the width direction of the absorber 4 in the top sheet 2 of the main body 10 and the top sheet 2 of the wing 6 The first mountain-folded portion, the second mountain-folded portion and the valley-folded portion formed in the central portion 12 of the top sheet 2 of the main body portion 10 are slightly different as described later.

As shown in FIG. 3, the top sheet 2 extends in the longitudinal direction (Y direction) in the region 14 and the wing portion 6 outside the side surfaces 41 in the width direction of the absorber 4 in the width direction (X direction) The first mountain fold 21 and the valley fold 23 are alternately arranged. The shape of the cross section of the first mountain fold 21 and the valley fold 23 is, for example, a substantially U-shape. The substantially U-shape includes, in addition to the U-shape, a shape that becomes a U-shape when it is deformed such as rounding corners or changing a straight line into a curve. For example, the substantially U-shape also includes V-shape, M-shape, trapezoid and Ω-shape.

The second mountain folds 22 preferably extend in a direction intersecting the first mountain folds 21 extending in the longitudinal direction (Y direction). For example, the angle between the direction in which the first mountain fold 21 extends and the direction in which the second mountain fold 22 extends is preferably 10 ° or more and 170 ° or less. The shape of the cross section of the second mountain fold 22 when the second mountain fold 22 is cut in a direction orthogonal to the direction in which the second mountain fold 22 extends is, for example, a substantially U-shape.

The number of first mountain folds 21 per cm in the width direction is preferably 3 or more, and more preferably 5 or more. If the number of first mountain-folded portions 21 per 1 cm in the width direction is 2 or less, the cushioning properties generated on the top sheet 2 by the first mountain-folded portions 21 may be weakened.

The length in the longitudinal direction (Y direction) of the second mountain-folded portion 22 is preferably 0.3 mm or more and 5 mm or less, more preferably 0.5 mm or more and 3 mm or less. When the length in the longitudinal direction (Y direction) of the second mountain fold 22 is smaller than 0.3 mm, the effect of making the first mountain fold 21 in the second mountain fold 22 less likely to collapse is reduced There is. When the length of the second mountain fold 22 in the longitudinal direction (Y direction) is larger than 5 mm, the cushioning property of the top sheet 2 may be weakened by the first mountain fold 21.

The absorbent article 1 is fixed to the undergarment by providing the top sheet 2 with the first mountain fold 21 and the second mountain fold 22 at least in the area 14 outside the side surfaces 41 in the width direction of the absorbent body 4. For this purpose, the first mountain fold 21 and / or the second mountain fold are present in the vicinity of the fold line 31 when the wing 6 is folded (see FIG. 6). The first mountain fold 21 and the second mountain fold 22 impart a soft touch to the surface of the absorbent article 1 by providing the top sheet 2 with cushioning properties. Therefore, when this wears the underwear equipped with the absorbent article 1, the touch around the foot of the underwear becomes good.

As shown in FIG. 4, the top sheet 2 of the central portion 12 of the main body 10 is the same as the top sheet 2 of the region 14 outside the side surfaces 41 of the main body 10 in the width direction and the wing 6. , A first mountain fold 21, a second mountain fold 22 and a valley fold 23. However, the first mountain fold 21, the second mountain fold 22 and the valley fold 23 of the top sheet 2 of the central portion 12 of the main body 10 have a blood modifying layer 24 described later on the surface on the skin side. Further include. Further, the first mountain fold 21 and the valley fold 23 of the top sheet 2 of the central portion 12 of the main body 10 further include an opening 25 described later.

A plurality of openings 25 aligned in the longitudinal direction (Y direction) on both side surfaces 26 of first mountain fold 21 and valley fold 23 of top sheet 2 of region 12 of main body 10 in which absorber 4 is provided. Is provided. The body fluid of the wearer discharged to the top sheet 2 of the area 12 where the absorber 4 of the main body 10 is provided passes through the opening 25 and moves to the absorber 4. In addition, the body fluid of the wearer discharged to the top sheet 2 quickly gathers toward the bottom of the valley fold portion 23 due to the substantially U shape of the cross section (X direction) cross section formed by the valley fold portion 23 . The body fluid flowing toward the bottom of the valley fold 23 passes through the opening 25 provided on the side 26 of the first mountain fold 21 and the valley fold 23 before reaching the valley fold 23. , Flows to the absorber 4. Further, the body fluid accumulated in the valley fold portion 23 also passes through the openings 25 provided on the side surfaces 26 of the first mountain fold portion 21 and the valley fold portion 23 and flows to the absorber 4. Therefore, the body fluid of the wearer is quickly absorbed by the absorbent body 4 by the openings 25 provided on the side surfaces 26 of the first mountain fold 21 and the valley fold 23. In addition, the amount of body fluid remaining in the top sheet 2 can be reduced by the openings 25 provided on the side faces 26 of the first mountain fold 21 and the valley fold 23.

A blood modifying agent may be applied to the skin side surface of the top sheet 2 of the central portion 12 of the main body portion 10 to form the blood modifying layer 24 on the skin contact side surface of the top sheet 2. The blood modifying agent layer 24 can prevent the body fluid of the wearer, in particular, highly viscous menstrual blood from remaining on the surface of the top sheet 2. The blood modifying agent layer 24 will be described in detail later.

Since the contact area between the skin of the wearer and the top sheet 2 is reduced by the first mountain fold 21 and the valley fold 23 provided on the top sheet 2 of the central portion 12 of the main body 10, the top sheet 2 Your skin feels good. In addition, it is not necessary to form only a 1st mountain fold part and a valley fold part in the top sheet 2 of the center part 12 of the main-body part 10, and to form a 2nd mountain fold part. Also in this case, since the contact area between the skin of the wearer and the top sheet 2 is reduced, the touch of the top sheet 2 is improved. However, by providing the second mountain fold portion, the first mountain fold portion is less likely to be crushed, so the first mountain fold portion, the second mountain fold portion is formed on the top sheet 2 of the central portion 12 of the main body portion 10. It is preferable to provide a section and a valley fold.

The back sheet 3 shown in FIGS. 1 and 2 prevents the body fluid absorbed by the absorber 4 from leaking out. The back sheet 3 is made of a material that is impermeable to body fluid. For example, as the back sheet 3, a hydrophobic non-woven fabric, an impermeable plastic film such as polyethylene and polypropylene or a laminate sheet of non-woven fabric and an impermeable plastic film, or the like is used. Alternatively, a spunbond-meltblown-spunbond (SMS) fibrous nonwoven fabric may be used as the back sheet 3 in which a highly water-resistant meltblown nonwoven fabric is sandwiched by strong spunbond nonwoven fabrics. By using a material having air permeability that does not pass body fluid as the back sheet 3, it is possible to reduce stuffiness when worn. The back sheet 3 is joined to the bottom of the valley fold 23 of the top sheet 2 using an adhesive such as a hot melt adhesive.

The absorber 4 absorbs and holds the body fluid. It is preferable that the absorber 4 is bulky, hard to lose its shape, and less in chemical stimulation. For example, a composite absorbent made of fluff pulp or air-laid non-woven fabric and super absorbent polymer (SAP) is used as the absorbent 4. The composite absorber may be covered with a liquid permeable material such as a tissue.

Also, instead of the fluff pulp of the composite absorbent, artificial cellulose fibers such as chemical pulp, cellulose fibers, rayon and acetate may be used. The basis weight of the absorbent fiber such as pulp in the composite absorbent is preferably 100 g / m ² or more and 800 g / m ² or less, and the mass ratio of the superabsorbent polymer in the composite absorbent is the absorbency The fiber content is preferably 100% to 10% to 65%. The basis weight of a liquid-permeable material such as a tissue covering the composite mixture is preferably 12 g / m ² or more and 30 g / m ² or less.

As the air-laid non-woven fabric of the composite mixture, for example, a non-woven fabric in which pulp and synthetic fibers are heat-sealed or a non-woven fabric in which pulp and synthetic fibers are fixed with a binder can be used.

The superabsorbent polymer of the composite absorbent has a three-dimensional network structure in which a water-soluble polymer is appropriately crosslinked. The absorbent polymer absorbs 30 to 60 times as much water as the volume of absorbent polymer before absorbing water. However, this absorbable polymer is essentially water insoluble. Also, the absorbent polymer does not release the water once absorbed, even if some pressure is applied. As this absorbent polymer, for example, starch-based, acrylic acid-based or amino acid-based particulate or fibrous polymers are used.

The shape and structure of the absorber 4 can be changed as needed, but the total amount of absorption of the absorber 4 needs to correspond to the designed insertion amount as the absorbent article 1 and the desired application. In addition, the size, absorption capacity and the like of the absorber 4 change depending on the application.

Absorber 4 is bonded to top sheet 2 using a hot melt adhesive. Thereby, it can suppress that the top sheet 2 peels from the absorber 4. As shown in FIG.

When the width of the crotch region of the undergarment is narrower than the width of the absorbent body 4 provided in the absorbent article 1, the folding prevention sheet 5 folds the wing portion 6 and attaches the absorbent article 1 to the underwear. The portion of the side surface 41 (see FIG. 1) of the absorbent body 4 is prevented from hitting the inner crotch of the wearer. In addition, when the width of the crotch region of the wearer's underwear is narrower than the width of the absorbent body 4 provided in the absorbent article 1, the folding suppression sheet 5 folds the wing portion 6 to make the absorbent article 1 underwear. When attached to the case, it is possible to suppress the occurrence of a large deflection in the portion of the side surface 41 of the absorber 4.

As shown to FIG. 1 and FIG. 2, the edge 51 of the width direction of the bending suppression sheet | seat 5 is located in the width direction outer side compared with the side 41 of the width direction of the absorber 4. As shown in FIG. Thereby, when the wing 6 is folded and the absorbent article 1 is attached to the undergarment, it is possible to suppress the wing 6 from being bent so that the portion of the side surface 41 of the absorber 4 has a fold.

If rigidity can be imparted to the absorbent article 1 so that the absorbent article 1 becomes difficult to bend compared to the area where the bending suppression sheet 5 is provided, compared to the area where the bending suppression sheet 5 is not provided, folding The sheet used as the music suppression sheet 5 is not particularly limited. However, if the rigidity of the absorbent folded sheet 5 is too high, the rigidity of the entire absorbent article 1 becomes too high, and the absorbent article 1 may cause a strong discomfort to the wearer. Therefore, it is preferable that the absorber folded sheet 5 have a rigidity of such a height that a strong discomfort does not occur even when worn by the wearer.

For example, the bending resistance measured by the cantilever method (JIS L 1096) in the bending suppression sheet 5 is preferably 15 to 120 mm, more preferably 30 to 70 mm. When the bending resistance by the cantilever method of the bending suppression sheet | seat 5 is smaller than 15 mm, it may be unable to suppress that the wing part 6 bends so that the part of the side 41 of the absorber 4 may become a crease. That is, when the wearer folds the wing portion 6 in order to attach the absorbent article to the undergarment, there may be a case where the bending suppression sheet 5 is bent at the side 41 of the absorber 4 together with the top sheet 2 and the back sheet 3 is there. Moreover, when the bending resistance by the cantilever method of the bending suppression sheet | seat 5 is larger than 120 mm, the rigidity of the absorbent article 1 becomes high too much, and the absorbent article 1 produces strong discomfort with respect to a wearer. There is.

The sheet used as the bending suppression sheet 5 is preferably a resin film, a perforated resin film, a woven fabric or a non-woven fabric, and more preferably a non-woven fabric. A non-woven fabric suitable for the bending suppression sheet 5 is, for example, a non-woven fabric of chemical fibers such as thermoplastic hydrophobic chemical fibers. Thermoplastic hydrophobic chemical fibers suitable for the bending suppression sheet 5 include, for example, single fibers such as polyethylene (PE), polypropylene (PP) and polyethylene terephthalate (PET), composite fibers obtained by graft polymerizing PE and PP, There is a composite fiber having a core-sheath structure.

When producing a non-woven fabric used for the bending suppression sheet 5, the web may be formed by a dry method such as a card method, a spun bond method, a meltblown method, an air laid method or a wet method. Moreover, when producing the nonwoven fabric used for the bending suppression sheet 5, you may perform bonding, such as thermal bonding, a needle punch, chemical bonding. For example, an SMS fiber non-woven fabric can be used for the bending suppression sheet 5.

The basis weight of the non-woven fabric used as the bending suppression sheet 5 is preferably 10 to 40 g / m ² , more preferably 13 to 20 g / m ² . If the basis weight of the non-woven fabric is smaller than 10 g / m ^2, it may not be possible to suppress bending of the wing portion 6 such that the portion of the side surface 41 of the absorber 4 has a fold. That is, when the wearer folds the wing portion 6 in order to attach the absorbent article to the undergarment, there may be a case where the bending suppression sheet 5 is bent at the side 41 of the absorber 4 together with the top sheet 2 and the back sheet 3 is there. Moreover, when the fabric weight of the nonwoven fabric is larger than 40 g / m ² , the rigidity of the absorbent article 1 becomes too high, and the absorbent article 1 may cause a strong discomfort to the wearer.

The sheet used as the bending suppression sheet 5 is preferably a sheet having hydrophobicity or water repellency. Thereby, it can suppress that the bodily fluid which exuded from absorber 4 leaks from the part of the cross direction of absorptive article 1 through bending control sheet 5.

The bending suppression sheet 5 is joined to the absorber 4 and the back sheet 3 by an adhesive such as a hot melt adhesive. However, the bending suppression sheet 5 is not joined to the top sheet 2. Thereby, the top sheet 2 can have a soft touch in the area | region of the width direction outer side of the side surface 41 of the absorber 4, without receiving to the influence of the bending suppression sheet | seat 5. FIG.

With reference to FIGS. 5 and 6, when the width of the crotch area of the wearer's underwear is narrower than the width of the absorbent body 4 provided in the absorbent article 1, the folding suppression sheet 5 is used. When it folds and attaches the absorbent article 1 to underwear, the principle which suppresses that the part of the side surface 41 of the absorber 4 hits a wearer's inner crotch is demonstrated. FIG. 5 is a view for explaining an absorbent article according to an embodiment of the present invention attached to the crotch region of the undergarment. FIG. 6 is a schematic cross-sectional view showing a cross section taken along the line BB of FIG. Reference numeral 70 in FIGS. 5 and 6 denotes the crotch area of the undergarment, and reference numeral 71 denotes the edge of the foot opening of the undergarment. From FIGS. 5 and 6, it can be seen that the width of the crotch region 70 of the wearer's underwear is narrower than the width of the absorbent body 4 provided in the absorbent article 1.

Since the absorbent article 1 is difficult to bend in the area where the folding prevention sheet 5 is provided, when the wearer folds the wing portion 6 and attaches the underwear to the crotch region 70 of the underwear, the wing portion 6 is The folds 31 of the absorbent article 1 produced when folded are substantially coincident with the edge 51 in the width direction of the anti-folding sheet 5. Therefore, as shown in FIG. 5 and FIG. 6, even if the position of the edge 71 of the foot opening of the undergarment overlaps with the position of the absorber 4, when the wing 6 is folded, the side 41 of the absorber 4 absorbs It is suppressed that the sex article 1 bends. Since this prevents the side surface 41 of the absorber 40 from protruding outward in the width direction, it is possible to suppress that the portion of the side surface 41 of the absorber 4 hits the inner crotch of the wearer. Further, when the wing portion 6 is folded, generation of a large deflection at the side surface 41 of the absorber 40 is suppressed, so that leakage of the body fluid of the wearer from the absorbent article 1 in the width direction can be suppressed.

Since the bending suppression sheet 5 is not provided to absorb the body fluid of the wearer, the thickness of the bending suppression sheet 5 is smaller than the thickness of the absorber 4. Therefore, the sense of incongruity which arises when the edge 51 in the width direction of the bending suppression sheet 5 hits the wearer's inner crotch is weaker than the sense of incongruity which occurs when the portion of the side surface 41 of the absorber 4 hits the wearer's crotch. Further, as described above, the top sheet 2 is provided with the first mountain fold portion 21. When the edge 51 in the width direction of the anti-folding sheet 5 hits the inner crotch of the wearer, the first mountain fold 21 acts as a cushion, and the edge 51 in the width direction of the anti-folding sheet 5 is the wearer's It can further reduce the sense of incongruity that occurs when hitting the inner crotch. That is, the first mountain fold 21 imparts cushioning properties to the top sheet 2, and further reduces the discomfort caused when the edge 51 in the width direction of the bending suppression sheet 5 hits the inner crotch of the wearer.

In addition, when the edge 51 in the width direction of the bending suppression sheet 5 can act as a cushion when hitting the inner crotch of the wearer, the protrusion formed on the top sheet 2 is the above-described first mountain-folded portion 21 And it is not limited to the 2nd mountain fold part. For example, a cylindrical protrusion, a prismatic protrusion, or the like may be formed on the top sheet 2. Moreover, it is not necessary to provide the protrusion which gives cushioning properties to the top sheet 2 in the whole top sheet, and should just be provided in the outer side of the both sides of the width direction of the said absorber at least.

As described above, the wing portion 6 is provided on the absorbent article 1 in order to stably fix the absorbent article 1 to the undergarment. The absorbent article 1 can be stably fixed to the undergarment by bending the wing portion 6 to the outer surface side of the undergarment and then sticking it to the crotch region of the undergarment through the adhesive portion 7. Further, the adhesive portion 7 is also provided to the main body portion 10, and the main body portion 10 is prevented from shifting and moving in the crotch region of the undergarment.

The adhesive unit 7 fixes the absorbent article 1 to the crotch area of the undergarment. As an adhesive which forms the adhesion part 7, what is a styrene-type polymer, a tackifier, and a plasticizer as a main component, for example is used suitably. Examples of the styrene-based polymer include styrene-ethylene-butylene-styrene block copolymer, styrene-butylene polymer, styrene-butylene-styrene block copolymer, and styrene-isobutylene-styrene copolymer. Or a blend of two or more polymers. Among these, styrene-ethylene-butylene-styrene block copolymer is preferable in that the thermal stability is good.

Further, as the tackifier and the plasticizer, those which are solid at normal temperature can be preferably used, and as the tackifier, for example, C5 petroleum resin, C9 petroleum resin, dicyclopentadiene petroleum resin, rosin petroleum resin And polyterpene resins, terpene phenol resins, etc., and examples of the plasticizer include, in addition to monomer plasticizers such as triflecil phosphate, dibutyl phthalate and dioctyl phthalate, polymer plasticizers such as vinyl polymers and polyesters. Be

As shown in FIGS. 1 and 2, the top sheet 2 and the absorbent body 4 have compressed grooves 8 extending from the top sheet 2 to the inside of the absorbent body 4 which are formed by being compressed in the thickness direction by embossing. The squeeze groove 8 suppresses the diffusion of the body fluid discharged to the central portion of the absorbent article 1 (the portion in contact with the excretory port of the wearer's body fluid) in the width direction (X direction). Moreover, it can suppress that the top sheet 2 peels from the absorber 4 by this. The squeeze groove 8 surrounds the central portion of the absorbent article 1 and has a continuous, substantially annular shape. In addition, the pressing groove 8 surrounding the center part of the absorbent article 1 may be partially disconnected. That is, the pressing groove 8 may have a discontinuous and substantially annular shape.

Further, the compression bonding of the top sheet 2 to the back sheet 3 by heat embossing forms the seal portions 9 on both sides in the longitudinal direction and both sides in the width direction of the absorbent article 1. Thereby, the top sheet 2 can be prevented from peeling off from the back sheet 3.

Next, the above-mentioned blood modifying agent layer 24 will be described in detail. The blood modifying agent of the blood modifying agent layer 24 is a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45.degree. C. or less, 100 g of water at 25.degree. It has a water solubility of 00 to about 0.00 to about 0.05 g.

IOB (Inorganic Organic Balance) is an index showing the balance of hydrophilicity and lipophilicity, and in the present specification, the following equation by Oda et al .:
IOB = value calculated by inorganic value / organic value.

The above inorganic values and organic values are described in Satoshi Fujita, "Presence of Organic Compounds and Organic Conceptual Diagram", Chemistry Vol. 11, No. 10 (1957) p. Based on the organic conceptual diagram described in 719-725). The organic and inorganic values of the major groups by Mr. Fujita are summarized in Table 1 below.

For example, in the case of an ester of C14 tetradecanoic acid and C12 dodecyl alcohol, the organic value is 520 (CH ₂ , 20 × 26) and the inorganic value is 60 (-COOR, 60 ×). Therefore, IOB = 0.12.

In the above blood modifying agent, the IOB is about 0.00 to about 0.60, preferably about 0.00 to about 0.50, and about 0.00 to about 0.40. More preferred is about 0 to about 0.30. This is because the lower the IOB, the higher the organicity and the higher the affinity to blood cells.

In the present specification, the "melting point" means the peak top temperature of an endothermic peak when changing from solid state to liquid state when measured at a temperature rising rate of 10 ° C./min in a differential scanning calorimeter. The melting point can be measured, for example, using a DSC-60 type DSC measurement apparatus manufactured by Shimadzu Corporation.

The blood modifying agent may be liquid or solid at room temperature as long as it has a melting point of about 45 ° C. or less, ie, even if the melting point is about 25 ° C. or more, or less than about 25 ° C. It may well have a melting point such as, for example, about -5.degree. C., about -20.degree. The reason why the melting point of the blood modifying agent is about 45 ° C. or less will be described later.

Although there is no lower limit to the melting point of the blood modifying agent, it is preferable that its vapor pressure is low. The vapor pressure of the blood modifying agent is preferably about 0.00 to about 0.01 Pa at 1 atm and 25 ° C., more preferably about 0.000 to about 0.001 Pa, and about 0 More preferably, it is from .0000 to about 0.0001 Pa. Considering that the absorbent article of the present disclosure is used in contact with the human body, the vapor pressure is preferably about 0.00 to about 0.01 Pa at 1 atm and 40 ° C., and about 0.000 to about 0.01 More preferably, it is about 0.001 Pa, and more preferably, about 0.0000 to about 0.0001 Pa. If the vapor pressure is high, it may be vaporized during storage, which may cause problems such as a decrease in the amount of blood modifying agent and an odor when worn.

In addition, the melting point of the blood modifying agent can be properly used depending on the weather, the length of wearing time, and the like. For example, in areas where the average temperature is less than about 10 ° C, menstrual blood may be excreted and then cooled by the ambient temperature by employing a blood modifying agent having a melting point of less than about 10 ° C. It is believed that blood modifying agents can stably modify blood. When the absorbent article is used for a long time, the melting point of the blood modifying agent is preferably higher in the range of 45 ° C. or less. It is because it is hard to be affected by sweat, friction at the time of wearing, etc., and it is difficult for the blood modifying agent to move even when worn for a long time.

For a water solubility of 0.00 to 0.05 g, add a 0.05 g sample to 100 g deionized water at 25 ° C., allow to stand for 24 hours, and after 24 hours, lightly stir as needed, Then, it can be measured by visually evaluating whether the sample has dissolved. As used herein, with regard to water solubility, "dissolving" includes cases where the sample is completely dissolved in deionized water to form a homogeneous mixture and cases where the sample is completely emulsified. "Complete" means that there is no clump of sample in deionized water.

In the art, the surface of the top sheet is coated with a surfactant for the purpose of changing blood surface tension and the like to rapidly absorb the blood. However, since the surfactant generally has high water solubility, the surfactant-coated top sheet is compatible with hydrophilic components (such as plasma) in the blood, rather the blood remains on the top sheet. There is a tendency to work. Since the above-mentioned blood modifying agent has low water solubility, unlike the conventionally known surfactants, it is considered that blood can be rapidly transferred to the absorber without remaining on the top sheet.

In the present specification, the solubility in 100 g of water at 25 ° C. may be simply referred to as “water solubility”.

In the present specification, “weight-average molecular weight” refers to a polydispersed compound (for example, a compound produced by sequential polymerization, an ester produced from a plurality of fatty acids and a plurality of aliphatic monohydric alcohols), and It is a concept that includes one compound (for example, one fatty acid and an ester formed from one aliphatic monohydric alcohol), and N _i molecular weight M _i molecules (i = 1 or i = 1) , 2...) In the system:
M _w = ΣN _i M _i ² / ΣN _i M _i
Means M _w determined by

In the present specification, the weight average molecular weight means a value in terms of polystyrene, which is determined by gel permeation chromatography (GPC). Examples of GPC measurement conditions include the following.
Model: High-performance liquid chromatogram Lachrom Elite manufactured by Hitachi High-Technologies Corporation
Column: Showa Denko KK SHODEX KF-801, KF-803 and KF-804
Eluent: THF
Flow rate: 1.0 mL / min Implanted volume: 100 μL
Detection: RI (differential refractometer)
In addition, the weight average molecular weight described in the Example of this specification is measured based on the said conditions.

The above blood modifying agent is preferably selected from the following (i) to (iii),
(I) Hydrocarbons,
(Ii) from a carbonyl group (-CO-) and an oxy group (-O-) inserted between (ii-1) a hydrocarbon moiety and (ii-2) a C-C single bond of the above-mentioned hydrocarbon moiety A compound having one or more same or different groups selected from the group consisting of: (iii) (iii-1) a hydrocarbon moiety, and (iii-2) a C—C single bond of the above-mentioned hydrocarbon moiety (Iii-3) one or more, same or different group selected from the group consisting of carbonyl group (-CO-) and oxy group (-O-) inserted between (iii-3) A compound having one or more and the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH), which substitutes a hydrogen atom,
And any combination thereof.

In the present specification, "hydrocarbon" means a compound consisting of carbon and hydrogen, and is a chain hydrocarbon, for example, paraffinic hydrocarbon (also referred to as alkane not containing double bond and triple bond) Olefinic hydrocarbons (containing one double bond, also called alkenes), acetylenic hydrocarbons (containing one triple bond, also called alkynes), and a group consisting of double bonds and triple bonds And hydrocarbons containing two or more bonds selected from, as well as cyclic hydrocarbons such as aromatic hydrocarbons and alicyclic hydrocarbons.

The hydrocarbon is preferably a chain hydrocarbon and an alicyclic hydrocarbon, more preferably a chain hydrocarbon, a paraffin hydrocarbon, an olefin hydrocarbon and two double bonds. It is more preferable that it is the hydrocarbon (it does not contain a triple bond) which contains above, and it is still more preferable that it is a paraffinic hydrocarbon. The chained hydrocarbons include straight chained hydrocarbons and branched chained hydrocarbons.

In the compounds (ii) and (iii), when two or more oxy groups (—O—) are inserted, each oxy group (—O—) is not adjacent. Accordingly, the compounds (ii) and (iii) do not include compounds in which the oxy group is continuous (so-called peroxides).

Further, in the compound of (iii) above, at least one hydrogen atom of the hydrocarbon moiety is a hydroxyl group (-) rather than a compound in which at least one hydrogen atom of the hydrocarbon moiety is substituted with a carboxyl group (-COOH). Compounds substituted with OH) are preferred. As shown in Table 1, since the carboxyl group binds to metals and the like in blood, and the inorganic value greatly increases from 150 to 400 or more, the blood modifying agent having a carboxyl group is used at the time of use This is because the IOB value may exceed about 0.60 and the affinity to blood cells may be reduced.

More preferably, the above blood modifying agent comprises the following (i ') to (iii'),
(I ') hydrocarbons,
(Ii ') (ii'-1) a hydrocarbon moiety, and (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO) inserted between a C-C single bond of the above-mentioned hydrocarbon moiety -), A compound having one or more same or different bonds selected from the group consisting of carbonate bond (-OCOO-), and ether bond (-O-), and (iii ') (iii'-) 1) Carbonyl bond (-CO-), ester bond (-COO-), carbonate bond (-OCOO) inserted between the hydrocarbon moiety and the C-C single bond of the above-mentioned hydrocarbon moiety (iii'-2) A carboxyl group (-), and one or more, same or different bond selected from the group consisting of an ether bond (-O-) and (iii'-3) a hydrogen atom of the above-mentioned hydrocarbon moiety -COOH Compounds having one or more same or different groups selected from the group consisting of) and hydroxyl groups (—OH),
And any combination thereof.

In the compounds of (ii ′) and (iii ′) above, two or more identical or different bonds are inserted, ie, a carbonyl bond (—CO—), an ester bond (—COO—), a carbonate bond (— When two or more identical or different bonds selected from OCOO-) and an ether bond (-O-) are inserted, each bond is not adjacent, and at least carbon is separated between each bond. One atom intervenes.

More preferably, the blood modifying agent has about 1.8 or less carbonyl bonds (-CO-) and 2 or less ester bonds (-COO-) per 10 carbon atoms in the hydrocarbon moiety. About 1.5 or less carbonate bond (-OCOO-), about 6 or less ether bond (-O-), about 0.8 or less carboxyl group (-COOH), and / or hydroxyl group (-OH) Or a compound having about 1.2 or less).

More preferably, the above blood modifying agent is any of the following (A) to (F),
(A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the above chain Ester with a compound having one carboxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety,
(B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the above chain Ether with a compound having one hydroxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety,
(C) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a (C1) linear hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the chain hydrocarbon moiety,
(D) A chain hydrocarbon moiety and an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-) inserted between the C-C single bond of the chain hydrocarbon moiety and the chain hydrocarbon moiety ), And a compound having any one bond selected from the group consisting of carbonate bonds (—OCOO—),
(E) polyoxy C ₂ -C ₆ alkylene glycol or its alkyl ester or alkyl ether, and (F) chain hydrocarbon
And any combination thereof. Hereinafter, the blood modifying agent according to (A) to (F) will be described in detail.

[(A) (A1) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and Ester with a compound having one carboxyl group replacing a hydrogen atom of a linear hydrocarbon moiety]
(A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the above chain Ester with a compound having one carboxyl group replacing hydrogen atoms in the cyclic hydrocarbon moiety (hereinafter sometimes referred to as “compound (A)”) has the above-mentioned IOB, melting point and water solubility And all hydroxyl groups may not be esterified.

(A1) a compound having a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atom of the above chain hydrocarbon portion (hereinafter sometimes referred to as “compound (A1)”) For example, chain hydrocarbon tetraols such as alkanetetraols such as pentaerythritol, chain hydrocarbon triols such as alkanetriols such as glycerin, and chain hydrocarbon diols such as alkane diols such as Glycol is mentioned.
Examples of (A2) a compound having a chain hydrocarbon portion and one carboxyl group replacing the hydrogen atom of the chain hydrocarbon portion (hereinafter sometimes referred to as “compound (A2)”) include, for example, And compounds in which one hydrogen atom on a hydrocarbon is substituted with one carboxyl group (—COOH), such as fatty acid.
Examples of the compound (A) include an ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid, an ester of (a ₂ ) chain hydrocarbon triol and at least one fatty acid, and (a ₃ And esters of linear hydrocarbon diols and at least one fatty acid.

[Ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid]
The ester of the above linear hydrocarbon tetraol and at least one fatty acid may be, for example, the following formula (1):

Tetraester of pentaerythritol with fatty acid, the following formula (2):

Triester of pentaerythritol with fatty acid, the following formula (3):

A diester of pentaerythritol with fatty acid, the following formula (4):

And monoesters of fatty acid with pentaerythritol.
(Wherein, R ¹ to R ⁴ are each a chain hydrocarbon)

As fatty acids (R ¹ COOH, R ² COOH, R ³ COOH, and R ⁴ COOH) constituting esters of pentaerythritol and fatty acids, esters of pentaerythritol and fatty acids have the above IOB, melting point and water solubility For example, saturated fatty acids such as C ₂ to C ₃₀ saturated fatty acids, for example, acetic acid (C ₂ ) (C ₂ represents a carbon number, R ¹ C, R ² C, R ³ C or R ⁴ C, which corresponds to the carbon number of R ² C, hereinafter the same), propanoic acid (C ₃ ), butanoic acid (C ₄ ) and isomers thereof, for example, 2-methylpropanoic acid (C ₄₎ ), pentanoic acid (C ₅₎ and isomers thereof such as 2-methylbutanoic acid (C _5), 2,2-dimethyl propanoic acid (C _5), hexanoic acid (C _6), heptanoic acid (C ₇₎ Octanoic acid (C ₈₎ and isomers thereof, e.g., 2-ethylhexanoic acid (C _8), nonanoic acid (C _9), decanoic acid (C _10), dodecanoic acid (C _12), tetradecanoic acid (C ₁₄₎ , Hexadecanoic acid (C ₁₆ ), heptadecanoic acid (C ₁₇ ), octadecanoic acid (C ₁₈ ), eicosanoic acid (C ₂₀ ), docosanoic acid (C ₂₂ ), tetracosanoic acid (C ₂₄ ), hexacosanoic acid (C ₂₆ ), Examples include octacosanoic acid (C ₂₈ ), triacontanic acid (C ₃₀ ) and the like, as well as their isomers (except those mentioned above).

The fatty acids can also be unsaturated fatty acids. Examples of the unsaturated fatty acids include C ₃ -C ₂₀ unsaturated fatty acids such as monounsaturated fatty acids such as crotonic acid (C ₄ ), myristoleic acid (C ₁₄ ), palmitoleic acid (C ₁₆ ), Oleic acid (C ₁₈ ), elaidic acid (C ₁₈ ), vacenic acid (C ₁₈ ), gadeuric acid (C ₂₀ ), eicosenic acid (C ₂₀ ), etc., diunsaturated fatty acids such as linoleic acid (C ₁₈ ), Eicosadienoic acid (C ₂₀ ) and the like, triunsaturated fatty acids such as linolenic acid, for example α-linolenic acid (C ₁₈ ) and γ-linolenic acid (C ₁₈ ), pinolenic acid (C ₁₈ ), eleostearic acid, For example, α-eleostearic acid (C ₁₈ ) and β-eleostearic acid (C ₁₈ ), meade acid (C ₂₀ ), dihomo-γ-linolenic acid (C ₂₀ ), eicosatrienoic acid (C ₂₀ ) Etc, tetra-unsaturated Fatty acid, e.g., stearidonic acid (C _20), arachidonic acid (C _20), eicosatetraenoic acid (C _20), etc., penta-unsaturated fatty acids, for example, bosseopentaenoic acid (C _18), eicosapentaenoic acid (C ₂₀ And the like, as well as partial hydrogenated adducts thereof.

The ester of pentaerythritol and fatty acid is an ester of pentaerythritol and fatty acid derived from saturated fatty acid, that is, an ester of pentaerythritol and saturated fatty acid, in consideration of the possibility of modification by oxidation etc. preferable. Further, as the ester of pentaerythritol and a fatty acid, in order to make IOB small and make it more hydrophobic, it is preferable to be a diester, a triester or a tetraester, and a triester or a tetraester is more preferable. And tetra-esters are more preferred.

In the tetraester of pentaerythritol and fatty acid, the total carbon number of fatty acids constituting the tetraester of pentaerythritol and fatty acid, that is, in the above formula (1), R ¹ C, R ² C, R ³ C and When the total number of carbons in the R ⁴ C portion is 15, the IOB is 0.60. Therefore, in the case of tetraester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total number of carbons is about 15 or more. Examples of the tetraester of pentaerythritol and fatty acid include pentaerythritol, hexanoic acid (C ₆ ), heptanoic acid (C ₇ ), octanoic acid (C ₈ ), for example, 2-ethylhexanoic acid (C ₈ ), These include tetraesters with nonanoic acid (C ₉ ), decanoic acid (C ₁₀ ) and / or dodecanoic acid (C ₁₂ ).

In the above-described triester of pentaerythritol and fatty acid, the total carbon number of the fatty acid constituting the triester of pentaerythritol and fatty acid, that is, the R ¹ C, R ² C and R ³ C moieties in the above formula (2) The IOB is 0.58 when the sum of the carbon numbers of these is 19. Therefore, in the case of the triester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 19 or more.

In the diester of pentaerythritol and fatty acid, the total carbon number of fatty acids constituting the diester of pentaerythritol and fatty acid, that is, the total carbon number of R ¹ C and R ² C in the above formula (3) is In the case of 22, the IOB is 0.59. Accordingly, in the diester of pentaerythritol and fatty acid, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 22 or more.

In the monoester of pentaerythritol and fatty acid, when the carbon number of the fatty acid constituting the monoester of pentaerythritol and fatty acid, that is, the carbon number of R ¹ C portion in the above formula (4) is 25, IOB is It will be 0.60. Therefore, in the monoester of pentaerythritol and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the fatty acid is about 25 or more. In the above calculation, the effects of double bond, triple bond, iso branch and tert branch are not taken into consideration.

Examples of commercially available esters of pentaerythritol and fatty acid include Unistar H-408 BRS, H-2408 BRS-22 (mixed product), etc. (all manufactured by NOF Corporation).

[Ester of (a ₂ ) chain hydrocarbon triol and at least one fatty acid]
The ester of the above linear hydrocarbon triol and at least one fatty acid may be, for example, the following formula (5):

Triester of glycerin and fatty acid, the following formula (6):

A diester of glycerin and a fatty acid, and the following formula (7):

(Wherein, each of R ⁵ to R ⁷ is a chain hydrocarbon)
And monoesters of glycerin and fatty acids.

As fatty acids (R ⁵ COOH, R ⁶ COOH and R ⁷ COOH) constituting the ester of glycerin and fatty acid, if the ester of glycerin and fatty acid satisfies the requirements of the above IOB, melting point and water solubility The fatty acids listed in the “ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid” are not particularly limited, and examples thereof include saturated fatty acids and unsaturated fatty acids, which are modified by oxidation etc. In consideration of the possibility of doing so, an ester of glycerin and a fatty acid derived from a saturated fatty acid, that is, an ester of glycerin and a saturated fatty acid is preferable.

Moreover, as ester of glycerol and a fatty acid, in order to make IOB small and to make it more hydrophobic, it is preferable that it is diester or triester, and it is more preferable that it is triester.

The above-mentioned triester of glycerin and fatty acid is also referred to as triglyceride, for example, triester of glycerin and octanoic acid (C ₈ ), triester of glycerin and decanoic acid (C ₁₀ ), glycerin and dodecanoic acid (C ₁₂ And triesters of glycerin with two or three fatty acids, and mixtures thereof.

Examples of the triester of the above glycerin and two or more fatty acids include triester of glycerin and octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ), glycerin, octanoic acid (C ₈ ), decane Acid (C ₁₀ ) and triester with dodecanoic acid (C ₁₂ ), glycerin and octanoic acid (C ₈ ), decanoic acid (C ₁₀ ), dodecanoic acid (C ₁₂ ), tetradecanoic acid (C ₁₄ ), hexadecanoic acid Examples thereof include triesters with (C ₁₆ ) and octadecanoic acid (C ₁₈ ).

As the above-mentioned triester of glycerin and fatty acid, in order to set the melting point to about 45 ° C. or less, the total carbon number of fatty acids constituting the triester of glycerin and fatty acid, ie, R ⁵ C in the formula (5) Preferably, the sum of the carbon numbers of the R ⁶ C and R ⁷ C moieties is about 40 or less.

Further, in the above-mentioned triester of glycerin and fatty acid, the total carbon number of fatty acids constituting the triester of glycerin and fatty acid, that is, in the formula (5), the R ⁵ C, R ⁶ C and R ⁷ C moieties When the total carbon number is 12, the IOB is 0.60. Therefore, in the above-mentioned triesters of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 12 or more. The above-mentioned triester of glycerin and a fatty acid is a so-called fat and is a component that can constitute the human body, and thus is preferable from the viewpoint of safety.

Commercial products of the above triester of glycerin and fatty acid include tricotic oil fatty acid glyceride, NA36, PANACET 800, PANACET 800B and PANACET 810S, and avian C2L oil fatty acid glyceride and triCL oil fatty acid glyceride (manufactured by NOF CORPORATION) Etc.).

The above-mentioned diester of glycerin and fatty acid is also referred to as diglyceride, for example, a diester of glycerin and decanoic acid (C ₁₀ ), a diester of glycerin and dodecanoic acid (C ₁₂ ), and glycerin and hexadecanoic acid (C ₁₆ ) Included are diesters and diesters of glycerin with two fatty acids, and mixtures thereof.

In the case of a diester of glycerin and a fatty acid, the total carbon number of fatty acids constituting the diester of glycerin and fatty acid, ie, the case where the total carbon number of R ⁵ C and R ⁶ C moieties in the formula (6) is 16 The IOB is 0.58. Therefore, in the case of the diester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of fatty acid is about 16 or more.

The monoester of glycerin and fatty acid is also referred to as monoglyceride, and examples thereof include icosanoic acid (C ₂₀ ) monoester of glycerin, docosanoic acid (C ₂₂ ) monoester of glycerin and the like. In the monoester of glycerin and fatty acid, the carbon number of fatty acid constituting the monoester of glycerin and fatty acid, that is, in the formula (7), the IOB is 0.59 when the carbon number of the R ⁵ C portion is 19 It becomes. Therefore, in the monoester of glycerin and fatty acid, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the fatty acid is about 19 or more.

[Ester of (a ₃ ) chain hydrocarbon diol and at least one fatty acid]
Examples of esters of the above linear hydrocarbon diol and at least one fatty acid include C ₂ to C ₆ linear hydrocarbon diols, such as C ₂ to C ₆ glycols, such as ethylene glycol, propylene glycol, butylene And mono- or diesters of glycol, pentylene glycol or hexylene glycol with fatty acids.

Specifically, as the ester of the above linear hydrocarbon diol and at least one fatty acid, for example, the following formula (8):
R ⁸ COOC _k H _2k OCOR ⁹ (8)
(Wherein k is an integer of 2 to 6 and R ⁸ and R ⁹ are each a chain hydrocarbon)
A diester of a C ₂ -C ₆ glycol with a fatty acid, and the following formula (9):
R ⁸ COOC _k H _2k OH (9)
(Wherein k is an integer of 2 to 6 and R ⁸ is a chain hydrocarbon)
And monoesters of fatty acid with C ₂ -C ₆ glycol.

In the ester of C ₂ to C ₆ glycol and fatty acid, as the fatty acid to be esterified (corresponding to R ⁸ COOH and R ⁹ COOH in the formula (8) and the formula (9)), C ₂ to C ₆ glycol No particular limitation is imposed on the ester of fatty acid with the fatty acid, provided that it satisfies the requirements of the above IOB, melting point and water solubility, for example, "ester of (a ₁ ) chain hydrocarbon tetraol with at least one fatty acid" The fatty acids listed in the above, ie, saturated fatty acids and unsaturated fatty acids, may be mentioned, and in view of the possibility of modification by oxidation etc., saturated fatty acids are preferred.

In the case of the diester of butylene glycol (k = 4) and a fatty acid shown in the formula (8), the IOB is 0.60 when the total carbon number of the R ⁸ C and R ⁹ C moieties is six. Therefore, in the case of the diester of butylene glycol (k = 4) and fatty acid shown in the formula (8), the IOB is about 0.00 to about 0.60 when the total carbon number is about 6 or more. Fulfill. Further, the monoester of a fatty acid ethylene glycol (k = 2) represented by formula (9), when the number of carbons of the R ⁸ C portion is 12, IOB is 0.57. Therefore, in the monoester of ethylene glycol (k = 2) shown in the formula (9) and a fatty acid, the requirement of an IOB of about 0.00 to about 0.60 when the carbon number of the fatty acid is about 12 or more Meet.

The ester of a C ₂ ~ C ₆ glycols and fatty acid, in view of the potential for degradation by oxidation and the like, derived from saturated fatty acids, esters of C ₂ ~ C ₆ glycols and fatty acid, Nachi Suwa, C ₂ It is preferably an ester of a -C ₆ glycol and a saturated fatty acid.

Also, as the ester of C ₂ -C ₆ glycol and fatty acid, an ester of glycol and fatty acid derived from glycol having a large number of carbon atoms, for example, butylene glycol, in order to make IOB small and make it more hydrophobic. It is preferable that it is an ester of a glycol derived from pentylene glycol or hexylene glycol and a fatty acid.

Furthermore, as the ester of C ₂ -C ₆ glycol and fatty acid, a diester is preferable in order to make IOB small and to make it more hydrophobic. Examples of commercial products of the ester of C ₂ -C ₆ glycol and fatty acid include Commol BL, Commol BS (manufactured by NOF Corporation) and the like.

[(B) a compound having a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and Ether with compound having one hydroxyl group replacing hydrogen atom of linear hydrocarbon moiety]
(B) A compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the above chain Ether with a compound having one hydroxyl group replacing hydrogen atoms in the cyclic hydrocarbon moiety (hereinafter sometimes referred to as “compound (B)”) has the above-mentioned IOB, melting point and water solubility And all hydroxyl groups may not be etherified.

Examples of the compound having (B1) a chain hydrocarbon portion and 2 to 4 hydroxyl groups replacing the hydrogen atoms of the above chain hydrocarbon portion are listed as the compound (A1) in the “compound (A)”. For example, pentaerythritol, glycerin and glycol.
Examples of (B2) a compound having a linear hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the linear hydrocarbon moiety (hereinafter may be referred to as “compound (B2)”) include, for example, A compound in which one hydrogen atom of hydrocarbon is substituted with one hydroxyl group (—OH), for example, aliphatic monohydric alcohol such as saturated aliphatic monohydric alcohol and unsaturated aliphatic monohydric alcohol Can be mentioned.

As the saturated aliphatic monohydric alcohol, for example, a C ₁ to C ₂₀ saturated aliphatic monohydric alcohol, for example, methyl alcohol (C ₁ ) (C ₁ represents a carbon number, the same applies hereinafter), ethyl alcohol C ₂ ), propyl alcohol (C ₃ ) and its isomers, such as isopropyl alcohol (C ₃ ), butyl alcohol (C ₄ ) and its isomers, such as sec-butyl alcohol (C ₄ ) and tert-butyl alcohol (C ₄ ), pentyl alcohol (C ₅ ), hexyl alcohol (C ₆ ), heptyl alcohol (C ₇ ), octyl alcohol (C ₈ ) and isomers thereof, such as 2-ethylhexyl alcohol (C ₈ ), nonyl alcohol (C ₉ ), decyl alcohol (C ₁₀ ), dodecyl alcohol (C ₁₂ ), tetradecyl al Call (C _14), hexadecyl alcohol (C _16), to heptadecyl alcohol (C _17), octadecyl alcohol (C _18), and eicosyl alcohol (C _20), and isomers thereof that are not listed in these Be

Examples of the unsaturated aliphatic monohydric alcohol include those obtained by replacing one of the C—C single bonds of the above saturated aliphatic monohydric alcohol with a C = C double bond, such as oleyl alcohol. It is commercially available from Shin Nippon Rika Co., Ltd. under the names of Rikacoll series and Angekoall series.

As compound (B), for example, an ether of (b ₁ ) chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, for example, monoether, diether, triether and tetraether, preferably diether, triether Ethers and tetraethers, more preferably triethers and tetraethers, and even more preferably tetraethers, ethers of (b ₂ ) chain hydrocarbon triols and at least one aliphatic monohydric alcohol, such as monoethers, diethers and the like triether, preferably diethers and triethers and more preferably tri-ether, and (b ₃₎ a chain hydrocarbon diol and at least one aliphatic monohydric ether alcohols, for example, mono- and diethers and, Mashiku diethers.

Examples of the ether of the above linear hydrocarbon tetraol and at least one aliphatic monohydric alcohol include the following formulas (10) to (13):

(Wherein, each of R ¹⁰ to R ¹³ is a chain hydrocarbon).
And tetraethers of pentaerythritol and aliphatic monohydric alcohols, triethers, diethers and monoethers.

Examples of the ether of the above linear hydrocarbon triol and at least one aliphatic monohydric alcohol include the following formulas (14) to (16):

(Wherein, R ¹⁴ to R ¹⁶ are each a chain hydrocarbon).
And triethers of glycerol and aliphatic monohydric alcohols, diethers and monoethers.

As the ether of the above linear hydrocarbon diol and at least one aliphatic monohydric alcohol, the following formula (17):
R ¹⁷ OC _n H _2n OR ¹⁸ (17)
(Wherein n is an integer of 2 to 6 and R ¹⁷ and R ¹⁸ are each a chain hydrocarbon)
Diethers of C ₂ -C ₆ glycols and aliphatic monohydric alcohols, and the following formula (18):
R ¹⁷ OC _n H _2n OH (18)
(Wherein n is an integer of 2 to 6 and R ¹⁷ is a chain hydrocarbon)
And monoethers of C ₂ -C ₆ glycols and aliphatic monohydric alcohols.

In the tetraether of pentaerythritol and aliphatic monohydric alcohol, the total carbon number of aliphatic monohydric alcohol constituting the tetraether of pentaerythritol and aliphatic monohydric alcohol, that is, in the above formula (10), When the total carbon number of the R ¹⁰ , R ¹¹ , R ¹² and R ¹³ moieties is 4, the IOB is 0.44. Therefore, in the above tetraether of pentaerythritol and aliphatic monohydric alcohol, IOB is required to be about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 4 or more. Fulfill.

In the triether of pentaerythritol and aliphatic monohydric alcohol, the total carbon number of aliphatic monohydric alcohol constituting triether of pentaerythritol and aliphatic monohydric alcohol, ie, in the above formula (11), When the sum of the carbon numbers of the R ¹⁰ , R ¹¹ and R ¹² moieties is 9, the IOB is 0.57. Therefore, in the above triether of pentaerythritol and aliphatic monohydric alcohol, IOB is required to be about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 9 or more. Fulfill.

In the diether of pentaerythritol and aliphatic monohydric alcohol, the total carbon number of aliphatic monohydric alcohols constituting the diether of pentaerythritol and aliphatic monohydric alcohol, that is, R ¹⁰ in the above formula (12) The IOB is 0.60 when the sum of the carbon numbers of the and R ¹¹ moieties is 15. Therefore, in the diether of pentaerythritol and aliphatic monohydric alcohol, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 15 or more. .

In the monoether of pentaerythritol and aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of pentaerythritol and aliphatic monohydric alcohol, that is, R ¹⁰ in the above formula (13) When the carbon number of the portion is 22, the IOB is 0.59. Therefore, in the monoether of pentaerythritol and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the aliphatic monohydric alcohol is about 22 or more.

In the above triether of glycerin and aliphatic monohydric alcohol, the total carbon number of aliphatic monohydric alcohol constituting triether of glycerin and aliphatic monohydric alcohol, that is, R in the formula (14) ^When the sum of the carbon numbers of ¹⁴ , R ¹⁵ and R ¹⁶ is 3, the IOB is 0.50. Therefore, in the above triether of glycerin and aliphatic monohydric alcohol, IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of aliphatic monohydric alcohol is about 3 or more. .

In the diether of glycerin and an aliphatic monohydric alcohol, the total carbon number of aliphatic monohydric alcohols constituting the diether of glycerin and an aliphatic monohydric alcohol, that is, in the formula (15), R ¹⁴ and R ¹⁵ When the total number of carbon atoms in the portion is 9, the IOB is 0.58. Therefore, in the diether of glycerin and an aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the total carbon number of the aliphatic monohydric alcohol is about 9 or more.

In the monoether of glycerin and aliphatic monohydric alcohol, the carbon number of the aliphatic monohydric alcohol constituting the monoether of glycerin and aliphatic monohydric alcohol, that is, the carbon of R ¹⁴ in the formula (16) When the number is 16, the IOB is 0.58. Therefore, in the monoether of glycerin and aliphatic monohydric alcohol, the IOB satisfies the requirement of about 0.00 to about 0.60 when the carbon number of the aliphatic monohydric alcohol is about 16 or more.

In the diether of butylene glycol (n = 4) represented by the formula (17) and an aliphatic monohydric alcohol, the IOB is 0.33 when the total carbon number of the R ¹⁷ and R ¹⁸ moieties is two. . Therefore, in the diether of butylene glycol (n = 4) shown in the formula (17) and an aliphatic monohydric alcohol, the IOB is about 0.00 when the total carbon number of the aliphatic monohydric alcohol is 2 or more. Meet the requirements of ~ 0.60. Further, in the monoether of ethylene glycol (n = 2) and aliphatic monohydric alcohol represented by the formula (18), the IOB is 0.60 when the carbon number of the R ¹⁷ portion is eight. Therefore, in the monoether of ethylene glycol (n = 2) and aliphatic monohydric alcohol shown in the formula (18), when the carbon number of the aliphatic monohydric alcohol is about 8 or more, IOB is about 0. Meet the requirements of 00 to about 0.60.

The compound (B) can be produced by dehydration condensation of the compound (B1) and the compound (B2) in the presence of an acid catalyst.

[(C) (C1) a chain hydrocarbon moiety and a carboxylic acid, hydroxy acid, alkoxy acid or oxo acid containing 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety; (C2) Ester of a compound having a linear hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the linear hydrocarbon moiety]
(C) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a (C1) linear hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety; C2) An ester of a chain hydrocarbon moiety and a compound having one hydroxyl group replacing the hydrogen atom of the chain hydrocarbon moiety (hereinafter sometimes referred to as “compound (C)”) is All carboxyl groups may not be esterified as long as they have the above IOB, melting point and water solubility.

(C1) a linear hydrocarbon moiety and a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing 2 to 4 carboxyl groups replacing the hydrogen atom of the linear hydrocarbon moiety (hereinafter referred to as “compound C1) may be, for example, a linear hydrocarbon carboxylic acid having 2 to 4 carboxyl groups, such as a linear hydrocarbon dicarboxylic acid, such as an alkane dicarboxylic acid, such as ethanedioic acid. Propanedioic acid, butanedioic acid, pentanedioic acid, hexanedioic acid, heptanedioic acid, octanedioic acid, nonanedioic acid and decanedioic acid, linear hydrocarbon tricarboxylic acids such as alkanetricarboxylic acids such as propane tricarboxylic acid Acid, butane triacid, pentane triacid, hexane triacid, heptane triacid, octane triacid, nonane triacid and decane triacid, and Chain hydrocarbon tetracarboxylic acids such as alkane tetracarboxylic acids such as butane tetra acid, pentane tetra acid, hexane tetra acid, heptane tetra acid, octane tetra acid, octane tetra acid, nonane tetra acid and decane tetra acid.

Further, in the compound (C1), a linear hydrocarbon hydroxy acid having 2 to 4 carboxyl groups, for example, a linear chain having 2 to 4 carboxyl groups, such as malic acid, tartaric acid, citric acid, isocitric acid, etc. Hydrocarbon alkoxy acids, such as O-acetyl citric acid, and linear hydrocarbon oxo acids having 2 to 4 carboxyl groups are included. Examples of the compound having a (C2) linear hydrocarbon moiety and one hydroxyl group replacing the hydrogen atom of the linear hydrocarbon moiety include those listed in the “compound (B)”, for example, Aliphatic monohydric alcohols are mentioned.

As the compound (C), an ester of a linear hydrocarbon tetracarboxylic acid having 4 carboxyl groups (c ₁ ), a hydroxy acid, an alkoxy acid or an oxo acid, and at least one aliphatic monohydric alcohol, for example, Mono-, di-, tri- and tetra-esters, preferably diesters, tri- and tetra-esters, more preferably tri- and tetra-esters, and still more preferably tetra-esters, chained with 3 (c ₂ ) carboxyl groups Esters of hydrocarbon tricarboxylic acids, hydroxy acids, alkoxy acids or oxo acids with at least one aliphatic monohydric alcohol, such as monoesters, diesters and triesters, preferably diesters and triesters, and more preferably triesters Ester, and (c ₃₎ a chain hydrocarbon dicarboxylic acids having two carboxyl groups, hydroxy acids, esters of alkoxy acids or oxoacids, and at least one aliphatic monohydric alcohol, for example, mono- and diesters, Preferably, diester is mentioned. Examples of the compound (C) include dioctyl adipate, tributyl O-acetyl citrate and the like, and are commercially available.

[(D) a linear hydrocarbon moiety and an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO) inserted between the C—C single bond of the above linear hydrocarbon moiety A compound having one or more bonds selected from the group consisting of-), and a carbonate bond (-OCOO-)]
(D) A chain hydrocarbon moiety and an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-) inserted between the C-C single bond of the chain hydrocarbon moiety and the chain hydrocarbon moiety And (d ₁ ) aliphatic as a compound having a bond selected from the group consisting of carbonate bond (—OCOO—) and any one bond (hereinafter may be referred to as “compound (D)”) Ethers of monohydric alcohols and aliphatic monohydric alcohols, (d ₂ ) dialkyl ketones, esters of (d ₃ ) fatty acids and aliphatic monohydric alcohols, and (d ₄ ) dialkyl carbonates can be mentioned.

[(D ₁ ) ether of aliphatic monohydric alcohol and aliphatic monohydric alcohol]
As the ether of the above aliphatic monohydric alcohol and aliphatic monohydric alcohol, the following formula (19):
R ¹⁹ OR ²⁰ (19)
(Wherein, R ¹⁹ and R ²⁰ are each a chain hydrocarbon)
And compounds having the formula:

As the aliphatic monohydric alcohol constituting the above ether (corresponding to R ¹⁹ OH and R ²⁰ OH in the formula (19)), if the above ether satisfies the requirements of the above IOB, melting point and water solubility It is not particularly limited, and examples thereof include aliphatic monohydric alcohols listed in the “compound (B)” section.

In the ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, the total carbon number of the aliphatic monohydric alcohol constituting the ether, that is, the carbon number of the R ¹⁹ and R ²⁰ moieties in the above formula (19) Since the IOB is 0.50 when the sum of the two is 2, the requirement of the above IOB is satisfied if the total carbon number is about 2 or more. However, when the total carbon number is about 6, the water solubility is as high as about 2 g, and there is also a problem from the viewpoint of the vapor pressure. In order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more.

[(D ₂ ) dialkyl ketone]
As said dialkyl ketone, following Formula (20):
R ²¹ COR ²² (20)
(Wherein, each of R ²¹ and R ²² is an alkyl group)
And compounds having the formula:

In the above-mentioned dialkyl ketone, since the IOB is 0.54 when the total carbon number of R ²¹ and R ²² is 5, the requirement of the above IOB is satisfied if the total carbon number is about 5 or more. However, when the total carbon number is about 5, the water solubility is as high as about 2 g. Therefore, in order to satisfy the requirement of water solubility of about 0.00 to about 0.05 g, the total carbon number is preferably about 8 or more. Also, in consideration of the vapor pressure, the carbon number is preferably about 10 or more, and preferably about 12 or more. When the total carbon number is about 8, for example, in the case of 5-nonanone, the melting point is about −50 ° C., and the vapor pressure is about 230 Pa at 20 ° C. The above-mentioned dialkyl ketone is commercially available and can be obtained by a known method, for example, oxidation of a secondary alcohol with chromic acid or the like.

[(D ₃ ) ester of fatty acid and aliphatic monohydric alcohol]
As ester of the said fatty acid and aliphatic monohydric alcohol, following Formula (21):
R ²³ COOR ²⁴ (21)
(Wherein, R ²³ and R ²⁴ are each a chain hydrocarbon)
And compounds having the formula:

Examples of the fatty acid (corresponding to R ²³ COOH in the formula (21)) constituting the above-mentioned ester are listed, for example, in “ester of (a ₁ ) chain hydrocarbon tetraol with at least one fatty acid”. A fatty acid, that is, a saturated fatty acid or an unsaturated fatty acid is mentioned, and considering the possibility of modification by oxidation etc., a saturated fatty acid is preferred. Examples of the aliphatic monohydric alcohol (corresponding to R ²⁴ OH in the formula (21)) constituting the above-mentioned ester include, for example, aliphatic monohydric alcohols listed in the “compound (B)” section.

In the ester of fatty acid and aliphatic monohydric alcohol, the sum of carbon number of fatty acid and aliphatic monohydric alcohol, that is, the sum of carbon number of R ²³ C and R ²⁴ in the formula (21) is 5 In this case, since the IOB is 0.60, the requirements of the above IOB are satisfied when the total carbon number of the R ²³ C and R ²⁴ moieties is about 5 or more. However, for example, with butyl acetate having a total of 6 carbon atoms, the vapor pressure is as high as 2,000 Pa or more. Therefore, in consideration of the vapor pressure, the total carbon number is preferably about 12 or more. If the total carbon number is about 11 or more, the water solubility can satisfy the requirement of about 0.00 to about 0.05 g.

Examples of esters of the above fatty acids with aliphatic monohydric alcohols include, for example, esters of dodecanoic acid (C ₁₂ ), dodecyl alcohol (C ₁₂ ), tetradecanoic acid (C ₁₄ ), and dodecyl alcohol (C ₁₂ ) Examples of commercially available esters of fatty acids and aliphatic monohydric alcohols include Electol WE 20 and Electol WE 40 (all manufactured by NOF Corporation).

[(D ₄ ) dialkyl carbonate]
As said dialkyl carbonate, following Formula (22):
R ²⁵ OC (= O) OR ²⁶ (22)
(Wherein, R ²⁵ and R ²⁶ are each an alkyl group)
And compounds having the formula:

In the above dialkyl carbonate, since the IOB is 0.57 when the total carbon number of R ²⁵ and R ²⁶ is 6, if the total carbon number of R ²⁵ and R ²⁶ is about 6 or more, Meet the requirements. In view of water solubility, the total carbon number of R ²⁵ and R ²⁶ is preferably about 7 or more, and more preferably about 9 or more. The above dialkyl carbonate is commercially available, and can be synthesized by the reaction of phosgene with alcohol, the reaction of formic acid chloride ester with alcohol or alcoholate, and the reaction of silver carbonate with alkyl iodide.

[(E) Polyoxy C ₂ -C ₆ alkylene glycol, or ester or ether thereof]
Examples of the above-mentioned polyoxy C ₂ -C ₆ alkylene glycol or ester or ether thereof (hereinafter sometimes referred to as compound (E)) include (e ₁ ) polyoxy C ₂ -C ₆ alkylene glycol, (e ₂ ) polyoxy C An ester of a ₂ to C ₆ alkylene glycol with at least one fatty acid, an ether of (e ₃ ) polyoxy C ₂ to C ₆ alkylene glycol and at least one aliphatic monohydric alcohol, (e ₄ ) polyoxy C ₂ to C ₆ An ester of an alkylene glycol with a linear hydrocarbon tetracarboxylic acid, a linear hydrocarbon tricarboxylic acid, or a linear hydrocarbon dicarboxylic acid, and (e ₅ ) polyoxy C ₂ -C ₆ alkylene glycol, with a linear hydrocarbon tetra And ethers with linear hydrocarbon triols or linear hydrocarbon diols. That. This will be described below.

[(E ₁ ) polyoxy C ₂ -C ₆ alkylene glycol]
Polyoxy C ₂ ~ C ₆ alkylene glycol, i) oxy C ₂ ~ C ₆ alkylene backbone, i.e., polyoxyethylene backbone, oxypropylene backbone, oxybutylene skeleton, from the group consisting of oxypentylene skeleton, and oxy hexylene backbone A homopolymer having any one selected skeleton and having hydroxy groups at both ends, ii) a block copolymer having two or more kinds of backbones selected from the above group and having hydroxy groups at both ends, Or iii) means a random copolymer having two or more skeletons selected from the above group and having hydroxy groups at both ends.

It said oxy C ₂ ~ C ₆ alkylene backbone, from the viewpoint of lowering the polyoxy C ₂ ~ C ₆ IOB of alkylene glycols, polyoxypropylene skeleton, oxybutylene skeleton, it is oxypentylene skeleton, or an oxy hexylene skeleton preferably More preferably, they are an oxybutylene skeleton, an oxypentylene skeleton, or an oxyhexylene skeleton.

The above polyoxy C ₂ -C ₆ alkylene glycol has the following formula (23):
_{HO- (C m H 2m O)} n -H (23)
(In the formula, m is an integer of 2 to 6)
Can be represented by

As confirmed by the present inventor, polyethylene glycol (corresponding to a homopolymer of m = 2 in the formula (23)) is about 0 when n045 (weight average molecular weight is more than about 2,000). Even though the weight average molecular weight exceeded about 4,000, it did not meet the requirement of water solubility, although it met the requirement of an IOB of .00 to about 0.60. Therefore, (e ₁ ) polyoxy C ₂ -C ₆ alkylene glycol is considered not to include homopolymers of ethylene glycol, and ethylene glycol (e ₁ ) as a block copolymer or random copolymer with other glycols It should be included in the polyoxy C ₂ -C ₆ alkylene glycol.

Thus, homopolymers of formula (23) may include homopolymers of propylene glycol, butylene glycol, pentylene glycol or hexylene glycol. From the above, in the formula (23), m is about 3 to about 6, and more preferably about 4 to about 6, and n is 2 or more.

In the above formula (23), the value of n is that the poly C ₂ -C ₆ alkylene glycol has an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and 100 g of water at 25 ° C. It is a value that has a water solubility of about 0.00 to about 0.05 g. For example, when formula (23) is polypropylene glycol (m = 3 homopolymer), IOB is 0.58 when n = 12. Therefore, when the formula (23) is polypropylene glycol (m = 3 homopolymer), the above IOB requirement is satisfied when m ≧ about 12. In the case where the formula (21) is polybutylene glycol (m = 4 homopolymer), the IOB is 0.57 when n = 7. Therefore, when the formula (23) is polybutylene glycol (m = 4 homopolymer), the above IOB requirement is satisfied when n ≧ about 7.

From the viewpoint of IOB, melting point and water solubility, the weight average molecular weight of the polyoxy C ₂ -C ₆ alkylene glycol is preferably about 200 to about 10,000, more preferably about 250 to about 8,000, and more preferably It is in the range of about 250 to about 5,000. Also, in view of IOB, melting point and water solubility, the weight average molecular weight of the poly C ₃ alkylene glycol, ie, polypropylene glycol, is preferably about 1,000 to about 10,000, more preferably about 3,000 to about 8 And more preferably in the range of about 4,000 to about 5,000. When the weight average molecular weight is less than about 1,000, the water solubility does not satisfy the requirements, and the larger the weight average molecular weight, the more the absorber transfer rate and the top sheet whiteness tend to be improved.

Examples of commercial products of polyoxy C ₂ ~ C ₆ alkylene glycol, e.g., UNIOL (TM) D-1000, D-1200 , D-2000, D-3000, D-4000, PB-500, PB-700, PB -1000 and PB-2000 (manufactured by NOF Corporation).

[Ester of (e ₂ ) polyoxy C ₂ -C ₆ alkylene glycol with at least one fatty acid]
The ester of the polyoxy C ₂ to C ₆ alkylene glycol and at least one fatty acid is the OH terminal of the polyoxy C ₂ to C ₆ alkylene glycol described in the section “(e ₁ ) polyoxy C ₂ to C ₆ alkylene glycol”. One or both of which are esterified with fatty acids, ie, monoesters and diesters.

In the ester of polyoxy C ₂ -C ₆ alkylene glycol and at least one fatty acid, the fatty acid to be esterified is, for example, listed in “ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid”. Fatty acids, that is, saturated fatty acids or unsaturated fatty acids, and in view of the possibility of modification by oxidation etc., saturated fatty acids are preferred. Examples of commercially available esters of the polyoxy C ₂ -C ₆ alkylene glycol and fatty acid include Wilbright cp 9 (manufactured by NOF Corporation).

[(E ₃ ) Ether of polyoxy C ₂ -C ₆ alkylene glycol and at least one aliphatic monohydric alcohol]
The ether and at least one aliphatic monohydric alcohol and polyoxy C ₂ ~ C ₆ alkylene glycol, "(e ₁₎ polyoxy C ₂ ~ C ₆ alkylene glycol" polyoxy C ₂ ~ C ₆ alkylene which is described in the Those in which one or both of the OH ends of the glycol are etherified with an aliphatic monohydric alcohol, that is, monoethers and diethers are mentioned. Examples of aliphatic monohydric alcohols to be etherified in the ether of polyoxy C ₂ -C ₆ alkylene glycol and at least one aliphatic monohydric alcohol include, for example, aliphatics listed in the “compound (B)” section. Monohydric alcohol is mentioned.

[Ester of (e ₄ ) polyoxy C ₂ -C ₆ alkylene glycol with chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid]
And polyoxy C ₂ ~ C ₆ alkylene glycol and a chain hydrocarbon tetracarboxylic acid, in an ester of a chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acids, as the polyoxy C ₂ ~ C ₆ alkylene glycol to be esterified It is polyoxy C ₂ ~ C ₆ alkylene glycol described in "(e ₁₎ polyoxy C ₂ ~ C ₆ alkylene glycol" section and the like. Further, as the chain hydrocarbon tetracarboxylic acid to be esterified, the chain hydrocarbon tricarboxylic acid, and the chain hydrocarbon dicarboxylic acid, those described in the “compound (C)” can be mentioned.

The esters of the above polyoxy C ₂ -C ₆ alkylene glycol with chain hydrocarbon tetracarboxylic acid, chain hydrocarbon tricarboxylic acid, or chain hydrocarbon dicarboxylic acid are commercially available, and chain hydrocarbon tetracarbons are also commercially available. It can be produced by polycondensation of C ₂ -C ₆ alkylene glycol with an acid, linear hydrocarbon tricarboxylic acid or linear hydrocarbon dicarboxylic acid under known conditions.

[(E ₅ ) Ether of polyoxy C ₂ -C ₆ alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol]
And polyoxy C ₂ ~ C ₆ alkylene glycol and a chain hydrocarbon tetraol, chain hydrocarbon triol or in an ether of a chain hydrocarbon diol, as the polyoxy C ₂ ~ C ₆ alkylene glycol to be etherified, " (e ₁₎ polyoxy C ₂ ~ polyoxy C ₂ ~ C ₆ alkylene glycol is described in the section of C ₆ alkylene glycol "may be mentioned. Moreover, as the chain hydrocarbon tetraol to be etherified, the chain hydrocarbon triol, and the chain hydrocarbon diol, those described in the “compound (A)” section, for example, pentaerythritol, glycerin and glycol Can be mentioned.

Examples of commercially available ethers of the above polyoxy C ₂ -C ₆ alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol are, for example, UnilobeTM 5TP-300 KB, and Uniol (trademark) TG-3000 and TG-4000 (made by NOF Corporation) can be mentioned. Unilube (TM) 5TP-300KB is a compound obtained by polycondensation of 65 moles of propylene glycol and 5 moles of ethylene glycol with 1 mole of pentaerythritol, and its IOB is 0.39, and the melting point is less than 45 ° C. And the water solubility was less than 0.05 g.

Uniol (TM) TG-3000 is a compound obtained by polycondensing 50 moles of propylene glycol with 1 mole of glycerin, its IOB is 0.42, its melting point is less than 45 ° C, and its water solubility is 0.05 g And the weight average molecular weight was about 3,000. Uniol (TM) TG-4000 is a compound obtained by polycondensing 70 moles of propylene glycol with 1 mole of glycerin, its IOB is 0.40, melting point is less than 45 ° C., and water solubility is 0.05 g And the weight average molecular weight was about 4,000.

The ether of the polyoxy C ₂ -C ₆ alkylene glycol and the chain hydrocarbon tetraol, chain hydrocarbon triol or chain hydrocarbon diol is also a chain hydrocarbon tetraol, chain hydrocarbon triol or It can be produced by adding a C ₂ -C ₆ alkylene oxide to a linear hydrocarbon diol under known conditions.

[(F) chain hydrocarbon]
The chain hydrocarbon has an IOB of 0.00 and an aqueous solubility of almost 0 g because the inorganic value is 0, and the blood has a melting point of about 45 ° C. or less. It may be included in the modifier. Examples of the chain hydrocarbon include (f ₁ ) chain alkanes such as straight chain alkanes and branched chain alkanes, and in the case of straight chain alkanes, for example, the melting point is about 45 ° C. or less In general, those containing 22 or less carbon atoms are included. Also, in consideration of the vapor pressure, those having 13 or more carbon atoms are generally included. In the case of a branched alkane, since the melting point may be lower at the same carbon number than a linear alkane, one having a carbon number of 22 or more may also be included. As a commercial item of the above-mentioned hydrocarbon, Pearl Reem 6 (NOF Corporation) is mentioned, for example.

The blood modifying agent, as discussed in detail in conjunction with the examples, has been found to at least have the effect of reducing blood viscosity and surface tension. Since the menstrual blood to be absorbed by the absorbent article contains proteins such as the endometrial wall as compared with normal blood, they act to connect the blood cells to each other, and the blood cells are in a continuous state. Cheap. Therefore, the menstrual blood to be absorbed by the absorbent article tends to have a high viscosity, and when the top sheet is a non-woven fabric or a woven fabric, menstrual blood tends to be clogged between fibers, and the wearer feels sticky. And it spreads and leaks on the surface of the top sheet.

In addition, a blood modifying agent having an IOB of about 0.00 to about 0.60 is highly organic and easily enters between blood cells, thereby stabilizing the blood cells and making it difficult for the blood cells to form a continuous structure. It is thought that can be done. It is considered that the absorber makes it easy to absorb menstrual blood by stabilizing the blood cells and making the blood cells less likely to form a continuous structure. For example, it is known that in absorbent articles containing an acrylic superabsorbent polymer, the so-called SAP, when menstrual blood is absorbed, blood cells that have undergone continuous change cover the SAP surface, making it difficult for the SAP to exhibit its absorption performance. By stabilizing blood cells, it is considered that SAP can more easily exhibit absorption performance. In addition, it is considered that the blood modifying agent having high affinity for red blood cells protects the red blood cell membrane, so that the red blood cells are less likely to be destroyed.

Next, with reference to FIG. 7, the manufacturing method of the absorbent article 1 in one embodiment of this invention is demonstrated. FIG. 7 is a figure for demonstrating the absorbent article manufacturing apparatus 100 used for the manufacturing method of the absorbent article 1 in one Embodiment of this invention. In the method of manufacturing the absorbent article 1, a process of forming a folding suppression sheet, a process of forming an absorber, a process of preparing a sheet for top sheet, a process of forming compressed grooves in a laminate, and a sheet for backsheet , Cutting the continuum of the absorbent article and applying a blood modifying agent to the absorbent article. In addition, the top sheet sheet used in the step of preparing the top sheet sheet includes a process of preparing the resin film sheet, a process of forming the recess in the resin film sheet, and a process of gear stretching the resin film sheet. It is manufactured by the manufacturing method of the seat for sheets.

In the step of forming the bending suppression sheet, the bending suppression sheet sheet 112 supplied from the bending suppression sheet sheet roll 110 is placed on the belt 120. Then, after applying a hot melt adhesive to the sheet 112 for bending suppression sheet with a coating device (not shown), the cutter 130 is used to cut the sheet 112 for bending suppression sheet into a predetermined shape and the bending suppression sheet Make

At the process of forming an absorber, the absorber 148 is formed on a bending suppression sheet. Pulverized pulp 142 is supplied to pattern drum 140 from a pulverized pulp supply device (not shown). A recess 144 is formed on the outer peripheral portion of the pattern drum 140 as a mold for packing crushed pulp. The inside of the pattern drum 140 is suctioned 146, and the crushed pulp 142 supplied to the pattern drum 140 is sucked into the recess 144 and compressed. Then, the pulp 142 compressed in the recess 144 is formed into the absorber 148. The absorber 148 is placed on the bending suppression sheet.

In the step of preparing the top sheet sheet, a hot melt adhesive is applied to the absorbent body 148 with a coating device (not shown), and then the top sheet sheet 216 manufactured by the top sheet sheet manufacturing method described later is used as the absorbent body 148. And the top sheet sheet 216 is adhered to the absorber 148.

In the step of forming the pressing groove in the laminate, the pressing device is used to form the pressing groove in the top sheet sheet 216, the absorber 148 and the laminate 262 of the bending suppression sheet. The laminate 262 passes between the upper roll 151 and the lower roll 152 of the embossing device 150. On the surface of the outer periphery of the upper roll 151, a convex portion (not shown) having a shape corresponding to the pressing groove 8 of the absorbent article 1 shown in FIG. 1 is provided. The lower roll 152 is a plain roll whose outer peripheral surface is smooth. By passing the laminate 262 between the upper roll 151 and the lower roll 152 of the embossing device 150, the portion of the laminate 262 corresponding to the compressed grooves 8 of the absorbent article 1 shown in FIG. 1 is in the thickness direction And compressed grooves are formed in the laminate 262.

In the step of preparing the backsheet sheet, an adhesive is applied to the backsheet sheet 162 supplied from the backsheet sheet roll 160 using a coating device (not shown), and then lamination is performed in which compressed grooves are formed. It is overlapped and adhered to the surface on the side of the bending suppression sheet of the body 154 to form a continuum 164 of the absorbent article.

In the step of cutting the continuum of the absorbent article, the cutter 170 is used to cut the continuum 164 of the absorbent article into the shape of the absorbent article to produce the absorbent article.

In the step of applying the blood modifying agent to the absorbent article, the above-described blood modifying agent 181 is applied to the central region of the absorbent article using the modifier application spray 180 to apply blood to the surface of the top sheet. Form a modifier layer.

The blood modifying agent 181 applied to the central region of the absorbent article may be applied at least to a portion that abuts on the excretory port of the wearer's body fluid. For example, the length in the lengthwise direction is preferably 50 mm or more, more preferably 100 mm or more, and the length in the width direction is preferably 10 mm or more, more preferably 30 mm or more, centering on the center of the absorbent article. A blood modifying agent may be applied to an area.

Although the blood modifying agent was applied after the step of cutting the continuum of the absorbent article, the blood modifying agent may be applied in the step of producing the top sheet described later. In the process of manufacturing the absorbent article, in order to prevent the applied blood modifying agent from falling off the absorbent article, the downstream stage of the manufacturing process of the absorbent article, for example, the blood just before packaging the absorbent article It is preferred to apply the modifier to the absorbent article.

In addition, the method of manufacturing the absorbent article 1 includes a step of forming an adhesive portion on the continuous body 164 of the absorbent article, a step of forming a seal portion on the continuous body 164 of the absorbent article, and the like.

Next, a method of manufacturing a top sheet will be described.

In the step of preparing the resin film sheet, as shown in FIG. 7, the resin film sheet 212 supplied from the roll 210 of the resin film sheet is supplied to the recess forming roll 220.

At the process of forming a recessed part in a resin film sheet, the resin film sheet 212 is made to pass the recessed part formation roll 220, and the resin film sheet 214 (refer FIG. 9) in which the recessed part 2141 was formed is produced. The recess forming roll 220 comprises a knurling roll 221 and a preheating roll 222 having a smooth surface.

FIGS. 8A and 8B show an example of the knurled roll 221. FIG. FIG. 8A is a view showing the entire knurled roll 221, and FIG. 8B is an enlarged view of a portion 223 having unevenness on the outer peripheral surface of the knurled roll 221. As shown in FIG. FIG. 8C shows an example of the preheating roll 222 having a smooth surface. A grid-like convex portion 224 is provided on the surface 223 of the knurled roll 221. As a result, a rhombus recess 225 is formed on the surface of the knurled roll 221. In addition, the shape of the recessed part 225 of the knurl roll 221 is not limited to a rhombus, You may be shapes, such as a square, a rectangle, a parallelogram, a trapezoid, a triangle, and a hexagon.

The center line spacing of the convex parts 224 arranged in parallel in the lattice-like convex parts 224, that is, the pitch of the lattice-like convex parts 224 is preferably 0.2 mm or more and 10 mm or less, more preferably 0.4 mm or more and 2 mm It is below. When the pitch of the grid-like convex portions 224 is less than 0.2 mm or greater than 10 mm, the concave portion may not be formed in the resin film. In addition, the width of the grid-like convex portion 224 is preferably 0.01 mm or more and 1 mm or less, and more preferably 0.03 mm or more and 0.1 or less. Further, the length of one side of the rhombic recess 225 is preferably 0.1 mm or more and 5 mm or less, and more preferably 0.2 mm or more and 1 mm or less. When the width of the grid-like convex part 224 is less than 0.01 mm or more than 1 mm, or when the length of one side of the rhombus concave part 225 is less than 0.1 mm or more than 5 mm, the concave part may not be formed in the resin film. .

The preheated roll 222 having a smooth surface is maintained at a temperature of 70 ° C. or more and 100 ° C. or less, and heats the supplied resin film sheet 212. Thereby, the resin film sheet 212 becomes soft and easy to form.

When the resin film sheet 212 passes between the knurled roll 221 and the roll 222 having a smooth surface, the resin film sheet 212 receives a strong pressure in the thickness direction in a portion in contact with the grid-like convex portion 224. Thereby, as shown in FIG. 9, the fine recessed part 2141 is formed in the resin film sheet 214. As shown in FIG. In fact, the number of recesses 2141 formed in the resin film sheet 212 is smaller than that shown in FIG. 9, and the number of recesses 2141 per unit area is also much larger than that shown in FIG. The concave portion 2141 is formed only in a range 2143 corresponding to the central portion 12 (see FIG. 1) of the main body portion 10 in the resin film sheet 214. Here, the range corresponding to the absorbent article 1 in the resin film sheet 214 is the range indicated by the dotted line 2142.

In the step of gear-drawing the resin film sheet, the first mountain fold portion, the second mountain fold portion, and the second mountain fold portion of the top sheet 2 are caused to pass through the resin film sheet 214 having the concave portion formed in the stretching gear roll 230 shown in FIG. The valley folds are formed in the resin film sheet 214. The code | symbol 216 is a resin film sheet which formed the 1st mountain fold part, the 2nd mountain fold part, and the valley fold part.

The drawing gear roll 230 includes an upper roll 231 and a lower roll 232. 10 (a) is a view for explaining the upper roll 231 of the drawing gear roll 230, and FIG. 10 (b) is a view for explaining the gear teeth 233 arranged on the outer peripheral surface of the upper roll 231. FIG. 10 (c) is a cross-sectional view taken along the line CC of FIG. 10 (b). The gear teeth 233 extend discontinuously in the circumferential direction of the upper roll 231. That is, the gear teeth 233 extending in the circumferential direction of the upper roll 231 are interrupted at multiple points along the way. A second mountain-folded portion is formed in the resin film sheet 214 by the portion 234 where the gear teeth 233 are disconnected.

The width of gear teeth 233 is, for example, 0.3 mm or more and 0.5 mm or less, and the distance between the centers of adjacent gear teeth 233 is, for example, 1.0 mm or more and 1.2 mm or less.

11 (a) is a view for explaining the lower roll 232 of the drawing gear roll 230, and FIG. 11 (b) is a view for explaining the gear teeth 235 disposed on the outer peripheral surface of the lower roll 232. 11 (c) is a cross-sectional view taken along the line DD of FIG. 11 (b). The gear teeth 235 extend in the circumferential direction of the lower roll 232. Like the upper roll 231, the lower roll 232 is not interrupted at multiple points along the way. The width of the gear teeth 235 is, for example, equal to the width of the gear teeth 233 of the upper roll 231, and the distance between the centers of adjacent gear teeth 235 is, for example, equal to the distance between the centers of the gear teeth 233 of the upper roll 231.

The radial length of the upper roll 231 at the portion where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are engaged, that is, the biting depth is, for example, 1.25 mm. The gap between the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 when the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are engaged is, for example, 0.25 mm or more , 0.45 mm or less.

As shown in FIG. 7, when the resin film sheet 214 passes through the drawing gear roll 230, the resin film 214 is bent in a substantially wave shape, and the resin film 214 forms the first mountain fold 21 of the top sheet 2 and the second mountain fold. Portions 22 and valley folds 23 are formed. Further, an opening 25 (see FIG. 4) of the top sheet 2 is further formed in the region 2143 (see FIG. 9) in which the recess 2141 of the resin film sheet 214 is formed.

Next, with reference to FIG. 12, the principle of forming an opening in the resin film sheet 214 when the resin film sheet 214 passes through the drawing gear roll 230 will be described. Note that this principle does not limit the present invention.

The resin film sheet 214 is largely drawn at a portion 236 where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are engaged. The resin film sheet 214 is thin at the part where the concave part 2141 (see FIG. 9) is formed in the above-mentioned concave part forming step, and the part where the scratch is given by the grid-like convex part 224 of the knurling roll 221 As it is present, the strength is weak, and the recess 2141 of the resin film sheet 214 breaks when it is stretched. Therefore, in the stretched portion 236 of the resin film sheet 214, the concave portion 2141 of the resin film sheet 214 is torn, the torn portion of the resin film sheet 214 is spread, and the opening portion is to the torn portion of the resin film sheet 214. It is formed.

The resin film sheet 214 is not stretched much at the portions 237 and 238 where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are not engaged. For this reason, in the portions 237 and 238 in which the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 in the resin film sheet 241 are not engaged, the resin film sheet 214 described above The recess 2141 formed in the recess forming step is not broken and does not become an opening.

In the region where the concave portion 2141 of the resin film sheet 214 is not formed, even if the resin film sheet 214 is greatly stretched in the portion 236 where the gear teeth 233 of the upper roll 231 and the gear teeth 235 of the lower roll 232 are engaged The sheet 214 is not torn. For this reason, in the resin film sheet 214, the opening is not formed in the region 14 and the wing 6 respectively corresponding to the outer side 14 and the wing 6 of the both sides 41 in the width direction of the absorber 4 of the main body 10.

In the present invention, since the blood modifying agent has a mechanism to lower the viscosity and surface tension of the blood, the body fluid is transferred to the absorber 4 without remaining on the top sheet 2 by the blood modifying layer 24 and absorbed. 4 can be absorbed. The following examples confirmed that the blood modifying agent has a mechanism to lower the viscosity and surface tension of blood. This check was performed using a non-woven fabric in which the body fluid tends to remain as compared to the resin film.

[Example 1]
[Evaluation of rewet rate and absorber transfer speed]
[Blood modifier data]
A commercially available sanitary napkin was prepared. The sanitary napkin comprises a top sheet formed of an air through non-woven fabric (composite fiber of polyester and polyethylene terephthalate, basis weight: 35 g / m ² ) treated with a hydrophilic agent, and a composite of air through non-woven fabric (polyester and polyethylene terephthalate) Fiber, second sheet formed of basis weight: 30 g / m ² ), pulp (basis weight: 150 to 450 g / m ² , more in the central part), acrylic high absorption polymer (basis weight: 15 g / m ² ) And, it was formed from an absorbent including a tissue as a core wrap, a water repellent treated side sheet, and a back sheet made of polyethylene film.

The blood modifiers used in the experiments are listed below.
[Ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid]
-Unistar H-408 BRS, manufactured by NOF Corporation, pentaerythritol tetra 2-ethylhexanoate, weight average molecular weight: about 640
Unister H-2408 BRS-22, a mixture of NOF Corporation pentaerythritol tetra-2-ethylhexanoate and neopentyl glycol di-2-ethylhexanoate (58:42, weight ratio), weight average molecular weight: about 520

[Ester of (a ₂ ) chain hydrocarbon triol and at least one fatty acid]
· Cetiol SB 45 DEO, manufactured by Cognis Japan Ltd. Triester of glycerin and fatty acid in which the fatty acid is oleic acid or stearyl acid · SOY 42 manufactured by NOF Corporation C ₁₄ fatty acid: C ₁₆ fatty acid: C ₁₈ fatty acid: C ₂₀ fatty acids (including both saturated and unsaturated fatty acids) is approximately 0.2: 11: 88: 0.8 are contained in a weight ratio of triesters of glycerol with fatty acids, the weight average molecular weight: 880

Tri C2 L oil fatty acid glyceride, manufactured by NOF Corporation C ₈ fatty acid: C ₁₀ fatty acid: C ₁₂ fatty acid is contained in a weight ratio of approximately 37: 7: 56, triester of glycerin and fatty acid, Weight average molecular weight: about 570
Triethylene CL oil fatty acid glycerides, manufactured by NOF Corporation C ₈ fatty acid: fatty acid of C ₁₂ is approximately included in a weight ratio of 44:56, triesters of glycerin and fatty acid, the weight average molecular weight: about 570

Panaceto 810s, manufactured by NOF Corporation C ₈ fatty acid: Triester of glycerin and fatty acid containing C ₁₀ fatty acid at a weight ratio of approximately 85: 15, weight average molecular weight: about 480
-Panaceto 800, manufactured by NOF Corporation Triester of glycerin and fatty acid in which all fatty acids are octanoic acid (C ₈ ), weight average molecular weight: about 470

-Panaceto 800 B, manufactured by NOF Corporation Triester of glycerin and fatty acid in which all fatty acids are 2-ethylhexanoic acid (C ₈ ), weight average molecular weight: about 470
NA36, manufactured by NOF Corporation C ₁₆ fatty acids: C ₁₈ fatty acids: C ₂₀ fatty acids (including both saturated fatty acids and unsaturated fatty acids) in a weight ratio of approximately 5: 92: 3, Triester of glycerin and fatty acid, weight average molecular weight: about 880

· Tricot oil fatty acid glyceride, manufactured by NOF Corporation C ₈ fatty acid: C ₁₀ fatty acid: C ₁₂ fatty acid: C ₁₄ fatty acid: C ₁₆ fatty acid (including both saturated fatty acid and unsaturated fatty acid) is approximately 4 Triester of glycerin and fatty acid, contained in a weight ratio of 8: 60: 25: 3, weight average molecular weight: 670
・ Caprylic diglyceride, manufactured by NOF Corporation Diester of glycerin and fatty acid wherein fatty acid is octanoic acid, weight average molecular weight: 340

[Ester of (a ₃ ) chain hydrocarbon diol and at least one fatty acid]
-Commol BL, manufactured by NOF Corporation, dodecanoic acid (C ₁₂ ) monoester of butylene glycol, weight average molecular weight: about 270
・ Compol BS, manufactured by NOF Corporation Octadecanoic acid (C ₁₈ ) monoester of butylene glycol, weight average molecular weight: about 350
-Unistar H-208 BRS, manufactured by NOF Corporation Dipentyl 2-ethylhexanoate neopentyl glycol, weight average molecular weight: about 360

[(C ₂ ) ester of linear hydrocarbon tricarboxylic acid having 3 carboxyl groups, hydroxy acid, alkoxy acid or oxo acid, and at least one aliphatic monohydric alcohol]
-Tributyl O-acetyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd. Weight average molecular weight: about 400

[(C ₃ ) ester of linear hydrocarbon dicarboxylic acid having 2 carboxyl groups, hydroxy acid, alkoxy acid or oxo acid, and at least one aliphatic monohydric alcohol]
・ Dioctyl adipate, manufactured by Wako Pure Chemical Industries, Ltd. Weight average molecular weight: about 380

[(D ₃ ) ester of fatty acid and aliphatic monohydric alcohol]
Electol WE20, an oil-in-oil company ester of dodecanoic acid (C ₁₂ ) and dodecyl alcohol (C ₁₂ ), weight average molecular weight: about 360
Electol WE40, an ester of tetradecanoic acid (C ₁₄ ) manufactured by NOF Corporation, and dodecyl alcohol (C ₁₂ ), weight average molecular weight: about 390

[(E ₁ ) polyoxy C ₂ -C ₆ alkylene glycol]
Uniol D-1000, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,000
Uniol D-1200, polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,200
Uniol D-3000, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 3,000

Uniol D-4000, polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 4,000
Uniol PB500, polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 500
Uniol PB700, manufactured by NOF Corporation, polyoxybutylene polyoxypropylene glycol, weight average molecular weight: about 700

Uniol PB 1000 R, polybutylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1000
[Ester of (e ₂ ) polyoxy C ₂ -C ₆ alkylene glycol with at least one fatty acid]
· Wilbright cp 9, a compound in which OH groups at both ends of polybutylene glycol manufactured by NOF Corporation were esterified with hexadecanoic acid (C ₁₆ ), weight average molecular weight: about 1,150

[(E ₃ ) Ether of polyoxy C ₂ -C ₆ alkylene glycol and at least one fatty acid]
・ Unileub MS-70K, stearyl ether of polypropylene glycol manufactured by NOF Corporation, about 15 repeating units, weight average molecular weight: about 1,140

[(E ₅ ) Ether of polyoxy C ₂ -C ₆ alkylene glycol and chain hydrocarbon tetraol, chain hydrocarbon triol, or chain hydrocarbon diol]
・ Unileve 5TP-300KB
Polyoxyethylene polyoxypropylene pentaerythritol ether, weight average molecular weight: 4,130, produced by adding 5 moles of ethylene oxide and 65 moles of propylene oxide to 1 mole of pentaerythritol.

・ UNIOL TG-3000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 3,000
・ UNIOL TG-4000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 4,000

[(F ₁ ) chain alkane]
Pearl Reem 6, manufactured by NOF Corporation, branched chain hydrocarbon produced by copolymerizing liquid isoparaffin, isobutene and n-butene, and then adding hydrogen, degree of polymerization: about 5 to about 10, weight average molecular weight : About 330

[Other materials]
· NA50, a triester of glycerin and fatty acid in which hydrogen is added to NA36 manufactured by NOF Corporation and the ratio of double bonds derived from unsaturated fatty acid as a raw material is reduced, weight average molecular weight: about 880
・ (Caprylic acid / capric acid) monoglyceride, monoester of glycerin and fatty acid, which contains octanoic acid (C ₈ ) and decanoic acid (C ₁₀ ) manufactured by NOF Corporation at a weight ratio of about 85:15, Weight average molecular weight: about 220
Monomuls 90-L2 lauric acid monoglyceride, manufactured by Cognis Japan Ltd.

Isopropyl citrate, manufactured by Tokyo Chemical Industry Co., Ltd. Weight average molecular weight: about 230
・ Diisostearyl malate Weight average molecular weight: about 640
Uniol D-400, a polypropylene glycol manufactured by NOF Corporation, weight average molecular weight: about 400

-PEG 1500, polyethylene glycol manufactured by NOF Corporation, weight average molecular weight: about 1,500 to about 1,600
Nonion S-6, manufactured by NOF Corporation, polyoxyethylene monostearate, repeating unit of about 7 weight average molecular weight: about 880
Will Bright s 753, manufactured by NOF Corporation polyoxyethylene polyoxypropylene polyoxybutylene glycerin, weight average molecular weight: about 960

-Uniol TG-330, a glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 6 repeating units, weight average molecular weight: about 330
・ UNIOL TG-1000, glyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 16 repeating units, weight average molecular weight: about 1,000

・ Unirube DGP-700, a diglyceryl ether of polypropylene glycol manufactured by NOF Corporation, about 9 repeating units, weight average molecular weight: about 700
-Uniox HC60, manufactured by NOF Co., Ltd. polyoxyethylene hydrogenated castor oil, weight average molecular weight: about 3,570
・ Vaseline, Cognis Japan Ltd. Petroleum derived hydrocarbon, semi-solid

The IOB, melting point and water solubility of the above sample are shown in Table 2 below. The water solubility was measured according to the above-mentioned method, but 20.0 g was added to 100 g of demineralized water, and a sample dissolved after 24 hours was evaluated as "20 g <", and 100 g of demineralized water was used. A sample in which 0.05 g was dissolved but not 1.00 g was evaluated as 0.05 to 1.00 g. Moreover, regarding melting | fusing point, "<45" means that melting | fusing point is less than 45 degreeC.

The skin contact surface of the top sheet of the above-mentioned sanitary napkin was coated with the above-mentioned blood modifier. Heat each blood modifier to its melting point + 20 ° C if the blood modifier is liquid at room temperature, and if the blood modifier is solid at room temperature, then control seam HMA gun Each blood modifying agent was atomized and applied to the entire skin contact surface of the top sheet so that the basis weight was approximately 5 g / m ² .

FIG. 13 is an electron micrograph of the skin contact surface of the top sheet in the sanitary napkin (No. 2-5) in which the top sheet contains avian C2L oil fatty acid glyceride. As apparent from FIG. 13, the tri-C2L oil fatty acid glyceride is in the form of fine particles and adheres to the surface of the fiber.
Rewet rates and absorber transfer rates were measured according to the procedure described above. The results are shown in Table 2 below.

[Test method]
Place a perforated acrylic plate (200 mm x 100 mm, 125 g, with a 40 mm x 10 mm hole in the center) on the top sheet containing each blood modifying agent, and from the holes, 37 ± 1 ° C 3g of equine EDTA blood (into the blood of the horse, ethylenediaminetetraacetic acid (hereinafter referred to as "EDTA") added to prevent coagulation) was dropped (first time) using a pipette, and one minute later Then, 3 g of equine EDTA blood at 37 ± 1 ° C. was pipetted again from the hole of the acrylic plate (second time).

After the second drop of blood, immediately remove the above acrylic plate and place 10 sheets of filter paper (Advantec Toyo Co., Ltd. Qualitative filter paper No. 2, 50 mm x 35 mm) in the place where the blood is dropped, and 30 g of pressure from above The weight was placed to be / cm ² . One minute later, the filter paper was taken out, and the "rewet rate" was calculated according to the following equation.
Rewet rate (%) = 100 × (weight of filter paper after test−weight of original filter paper) / 6

In addition to the evaluation of the rewet rate, “absorber transfer speed”, which is the time for blood to transfer from the top sheet to the absorber after the second drop of blood, was measured. The above-mentioned absorber transfer rate means the time from when blood is introduced into the top sheet to when the red color of blood is not seen on the surface and inside of the top sheet.
The results of the rewet rate and the absorber transfer rate are shown in Table 2 below.

Next, the whiteness of the skin contact surface of the top sheet after the test of the absorber transfer speed was visually evaluated according to the following criteria.
◎: Almost no blood red remains, and there is no distinction between where blood was present and where it did not exist ○: Some blood red remains, but where blood was present, It is difficult to distinguish where it does not exist :: Some redness of the blood remains, and the place where the blood exists is known ×: The redness of the blood remains The results are also shown in Table 2 below. Show.

In the absence of a blood modifying agent, the rewet rate was 22.7% and the absorber transfer rate was over 60 seconds, but both the glycerin and fatty acid triesters had rewet rates From the fact that it is 7.0% or less and the absorber transfer rate is 8 seconds or less, it can be seen that the absorption performance is greatly improved. However, among triesters of glycerin and fatty acid, NA50 of which the melting point exceeds 45 ° C. shows no significant improvement in the absorption performance.

Similarly, a blood modifying agent having an IOB of about 0.00 to about 0.60, a melting point of about 45 ° C. or less, and an aqueous solubility of about 0.00 to about 0.05 g per 100 g of water at 25 ° C. It was found that the absorption performance was greatly improved.

Next, No. No. 2 to No. 2-2-47 sanitary napkins were worn by a plurality of volunteer subjects. With sanitary napkins containing blood modifiers 2-1 to 2-3, there was no tackiness on the top sheet even after menstrual blood absorption, and it was answered that the top sheet was smooth. .

Also, no. 2-1 to No. No. 2-32 sanitary napkins, and in particular. In the sanitary napkins containing blood modifiers 2-1 to 11, 15 to 19 and 32, the skin contact surface of the top sheet after absorption of menstrual blood is not stained red with blood and there is less discomfort I got an answer with.

[Example 2]
Rewet rates were assessed for the various blood of the animals according to the procedure described above. The blood used for the experiment is as follows.
[Animal species]
(1) human (2) horse (3) sheep

[Blood type]
Defibrillation blood: after blood collection, stirred for about 5 minutes in an Erlenmeyer flask together with glass beads EDTA blood: Addition of 0.5 mL of 12% EDTA · 2K saline to 65 mL of venous blood

[Fraction]
Serum or plasma: Supernatant after centrifuging defibrillated blood or EDTA blood, respectively, at about 1900 G at room temperature for 10 minutes Blood cells: Remove the serum from the blood and remove the residual phosphate buffered saline (PBS) ) Washed twice and then added with phosphate buffered saline for the removed serum

An absorbent article was produced in the same manner as in Example 2 except that avian C2L oil fatty acid glyceride was applied so as to give a basis weight of approximately 5 g / m ^2, and the rewet rate was evaluated for the above various blood. . Three measurements were taken for each blood and the mean value was taken.
The results are shown in Table 3 below.

The same tendency as equine EDTA blood obtained in Example 2 was also obtained in human and sheep blood. The same tendency was also observed in defibrinated blood and EDTA blood.

[Example 3]
[Evaluation of blood retention]
The blood retention of the top sheet containing the blood modifying agent and the top sheet not containing the blood modifying agent was evaluated.

[Test method]
(1) Using a control seam HMA gun with tri-C2L oil fatty acid glyceride on the skin contact surface of the top sheet formed of air-through non-woven fabric (composite fiber consisting of polyester and polyethylene terephthalate, basis weight: 35 g / m ² ) It is atomized and applied so that the basis weight is approximately 5 g / m ² . Also, for comparison, those not coated with tri-C2L oil fatty acid glyceride are also prepared. Then, both the top sheet coated with avian C2L oil fatty acid glyceride and the top sheet not coated are cut to a size of 0.2 g, and the mass of the cell strainer + top sheet (a) is accurately determined taking measurement.

(2) Add approximately 2 mL of horse EDTA blood from the skin contact side, and let it stand for 1 minute.
(3) Place a cell strainer in a centrifuge tube and spin down to remove excess equine EDTA blood.
(4) Measure the weight (b) of the top sheet containing Cell Trainer + Horse EDTA Blood.
(5) Calculate the initial absorption amount (g) per 1 g of top sheet according to the following formula.
Initial absorption amount = [weight (b)-weight (a)] / 0.2
(6) Re-set the cell strainer into a centrifuge tube and centrifuge at about 1200 G for 1 minute at room temperature.

(7) Measure the weight (c) of the top sheet containing Cell Trainer + Horse EDTA Blood.
(8) The absorbed amount after test (g) per 1 g of top sheet is calculated according to the following equation.
Absorption after test = [Weight (c)-Weight (a)] / 0.2
(9) The blood retention rate (%) was calculated according to the following equation.
Blood retention rate (%) = 100 × absorption after test / initial absorption The measurement was performed three times, and the average value was adopted. The results are shown in Table 4 below.

It is suggested that the top sheet containing the blood modifying agent has low blood retention and can be rapidly transferred to the absorber after absorbing blood.

[Example 4]
[Viscosity of blood containing blood modifying agent]
The viscosity of the blood containing the blood modifying agent was measured using Rheometric Expansion System ARES (Rheometric Scientific, Inc). 2% by weight of Panaceto 810s was added to equine defibrinated blood, the mixture was lightly stirred to form a sample, the sample was loaded on a parallel plate of 50 mm in diameter, the gap was made 100 μm, and the viscosity was measured at 37 ± 0.5 ° C. . Because of the parallel plate, the sample was not subjected to a uniform shear rate, but the average shear rate displayed on the instrument was 10 s ⁻¹ .

The viscosity of horse-defibrillated blood containing 2% by mass of Panaceto 810s was 5.9 mPa · s, while the viscosity of horse-defibrillated blood containing no blood modifying agent was 50.4 mPa · s. Thus, it can be seen that equine defibrinated blood containing 2% by weight of Panaceto 810s reduces the viscosity by about 90% as compared to the case without blood modifying agent. Although blood contains components such as blood cells and is known to have thixotropy properties, it is considered that the blood modifying agent of the present disclosure can lower the viscosity of blood in a low viscosity region. By reducing the viscosity of blood, it is thought that absorbed menstrual blood can be rapidly transferred from the top sheet to the absorber.

[Example 5]
[Micrograph of blood containing blood modifier]
A healthy volunteer's menstrual blood is collected on Saran wrap (registered trademark), and in part of it, Panaceto 810s dispersed in 10 times mass of phosphate buffered saline, and the concentration of Panaceto 810s is 1% by mass As it was added. The menstrual blood was applied to a slide glass, covered with a cover glass, and the condition of red blood cells was observed with a light microscope. A photomicrograph of menstrual blood containing no blood modifying agent is shown in FIG. 14 (a), and a photomicrograph of menstrual blood containing PANACET 810s is shown in FIG. 14 (b).

From FIG. 14, in the menstrual blood containing no blood modifying agent, red blood cells form a lump of rhomsen, etc., but in menstrual blood containing PANACET 810s, the red blood cells are dispersed stably. I understand. Therefore, it is suggested that the blood modifying agent works to stabilize red blood cells in the blood.

[Example 6]
[Surface tension of blood containing blood modifier]
The surface tension of blood containing a blood modifying agent was measured by a pendant drop method using a contact angle meter Drop Master 500 manufactured by Kyowa Interface Science Co., Ltd. The surface tension was measured after adding a predetermined amount of blood modifying agent to sheep defibrinated blood and shaking sufficiently. The measurement is automatically performed by the device, but the surface tension γ is obtained by the following equation (see FIG. 15).

γ = g × ρ × (de) ² × 1 / H
g: Gravitational constant 1 / H: correction term obtained from ds / de ρ: density de: maximum diameter ds: diameter at a position de up from the dropping end

The density ρ is the density test method and density / mass / volume conversion table in JIS K 2249-1995, 5. It was measured at the temperature shown in Table 5 below according to the vibrational density test method. For measurement, DA-505 of Kyoto Electronics Industries Ltd. was used. The results are shown in Table 5.

From Table 5, it is apparent from the fact that the blood modifying agent has a water solubility of about 0.00 to about 0.05 g per 100 g of water at 25 ° C., but its solubility in water is very low. It can be seen that the surface tension of the blood can be reduced. By lowering the surface tension of the blood, it is considered that the absorbed blood can be rapidly transferred to the absorber without being held between the fibers of the top sheet.

The above description is merely an example, and the invention is not limited to the above embodiment.

DESCRIPTION OF SYMBOLS 1 Absorbent article 2 top sheet 3 back sheet 4 absorber 5 bending suppression sheet 6 wing part 7 adhesive part 8 pressing groove 9 seal part 10 main body part 21 1st mountain fold part 22 2nd mountain fold part 23 valley fold Part 24 Blood modifier layer 25 Opening 26 Side of first mountain fold and valley fold 100 Non-woven fabric manufacturing device 110 Sheet roll for bending sheet 130, 170 Cutter 140 Pattern drum 150 Embossing device 160 for back sheet Roll 180 Modifier application spray 210 Roll of resin film sheet 212, 214, 216 Resin film sheet 220 Recess forming roll 230 Stretching gear roll 231 Upper roll 232 Lower roll 233, 235 Gear teeth 234 Gear teeth are broken

Claims (12)

1. A liquid-permeable top sheet provided on the skin side, having a longitudinal direction and a width direction, a liquid-impermeable back sheet provided on the clothing side, and a width provided between the top sheet and the back sheet Body portion provided with a liquid-retaining absorber including longitudinally extending side surfaces on both sides of the direction, and wing portions disposed on both sides of the body portion so as to extend in the width direction from both side edges of the body portion An absorbent article comprising
   The main body portion further includes a bending suppression sheet provided between the absorber and the back sheet and including longitudinally extending edges on both sides in the width direction,
   Edges on both sides in the width direction of the bending suppression sheet are positioned on the outer side in the width direction than the side surface of the absorber,
   The bending suppression sheet is rigid to the absorbent article such that the area in which the bending suppression sheet is provided is less likely to bend than the area in which the bending suppression sheet is not provided. An absorbent article to impart.
2. The absorbent article according to claim 1, wherein the bending resistance of the bending suppression sheet according to a cantilever method is 15 to 120 mm.
3. The absorbent article according to claim 1, wherein the anti-folding sheet is a non-woven fabric having a basis weight of 10 to 40 g / m ² .
4. The absorbent article according to any one of claims 1 to 3, wherein the anti-folding sheet has hydrophobicity or water repellency.
5. The absorbent article according to any one of claims 1 to 4, wherein the top sheet has a protrusion for providing a cushioning property to the top sheet at least outside of both side surfaces in the width direction of the absorber.
6. At least outside of both side surfaces in the width direction of the absorber, the top sheet extends in the longitudinal direction, and includes first mountain folds and valley folds alternately arranged in the width direction, and the first mountain folds. The absorbent article according to any one of claims 1 to 4, comprising a second mountain fold portion extending in a direction intersecting the portion.
7. The absorbent article according to any one of claims 1 to 6, wherein the bending suppression sheet is not joined to the top sheet.
8. The top sheet of the body portion includes the first mountain fold and the valley fold,
   A plurality of openings aligned in the longitudinal direction are provided on side surfaces of the first mountain fold and the valley fold,
   The top sheet of the body further includes a blood modifier layer on the skin side surface,
   The blood modifying agent layer has an IOB of 0.00 to 0.60, a melting point of 45 ° C. or less, and an aqueous solubility of 0.00 to 0.05 g in 100 g of water at 25 ° C. The absorbent article according to any one of claims 1 to 7, which has.
9. The blood modifying agent comprises the following (i) to (iii),
   (I) Hydrocarbons,
   (Ii) from a carbonyl group (-CO-) and an oxy group (-O-) inserted between (ii-1) a hydrocarbon moiety and (ii-2) a C-C single bond of the hydrocarbon moiety A compound having one or more same or different groups selected from the group consisting of: (iii) (iii-1) a hydrocarbon moiety, and (iii-2) a C—C single bond of said hydrocarbon moiety (Iii-3) one or more same or different groups selected from the group consisting of carbonyl group (—CO—) and oxy group (—O—) inserted between A compound having one or more and the same or different groups selected from the group consisting of a carboxyl group (—COOH) and a hydroxyl group (—OH), which substitutes a hydrogen atom,
   And selected from the group consisting of any combination thereof,
   The absorbent article according to claim 8, wherein, in the compound (ii) or (iii), when two or more oxy groups are inserted, each oxy group is not adjacent.
10. The blood modifying agent comprises the following (i ') to (iii'),
    (I ') hydrocarbons,
    (Ii ') (ii'-1) a hydrocarbon moiety, and (ii'-2) a carbonyl bond (-CO-), an ester bond (-COO) inserted between a C-C single bond of the hydrocarbon moiety -), A compound having one or more same or different bonds selected from the group consisting of carbonate bond (-OCOO-), and ether bond (-O-), and (iii ') (iii'-) 1) A carbonyl bond (-CO-), an ester bond (-COO-), a carbonate bond (-OCOO) inserted between a hydrocarbon moiety and (iii'-2) a C-C single bond of the hydrocarbon moiety A carboxyl group (-), and one or more, same or different bond selected from the group consisting of an ether bond (-O-) and (iii'-3) a hydrogen atom of the hydrocarbon moiety -COOH Compounds having one or more same or different groups selected from the group consisting of) and hydroxyl groups (—OH),
    And selected from the group consisting of any combination thereof,
    Here, in the compound of (ii ′) or (iii ′), in the case where two or more identical or different bonds are inserted, each bond is not adjacent. Goods.
11. The blood modifying agent comprises the following (A) to (F),
    (A) A compound having (A1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (A2) a chain hydrocarbon moiety, and the chain Ester with a compound having one carboxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety,
    (B) a compound having (B1) a chain hydrocarbon moiety and 2 to 4 hydroxyl groups replacing hydrogen atoms of the chain hydrocarbon moiety, (B2) a chain hydrocarbon moiety, and the chain Ether with a compound having one hydroxyl group replacing the hydrogen atom of the cyclic hydrocarbon moiety,
    (C) a carboxylic acid, a hydroxy acid, an alkoxy acid or an oxo acid containing a (C1) chain hydrocarbon moiety and 2 to 4 carboxyl groups replacing the hydrogen atom of the chain hydrocarbon moiety; C2) an ester of a compound having a chain hydrocarbon moiety and one hydroxyl group replacing a hydrogen atom of the chain hydrocarbon moiety,
    (D) an ether bond (-O-), a carbonyl bond (-CO-), an ester bond (-COO-) inserted between a chain hydrocarbon moiety and a C-C single bond of the chain hydrocarbon moiety ), And a compound having any one bond selected from the group consisting of carbonate bonds (—OCOO—),
    (E) polyoxy C ₂ -C ₆ alkylene glycol or its alkyl ester or alkyl ether, and (F) chain hydrocarbon
    The absorbent article according to any one of claims 8 to 10, selected from the group consisting of and any combination thereof.
12. The blood modifying agent is an ester of (a ₁ ) chain hydrocarbon tetraol and at least one fatty acid, an ester of (a ₂ ) chain hydrocarbon triol and at least one fatty acid, (a ₃ ) chain An ester of a hydrocarbon diol and at least one fatty acid, an ether of (b ₁ ) a chain hydrocarbon tetraol and at least one aliphatic monohydric alcohol, (b ₂ ) a chain hydrocarbon triol and at least one aliphatic Ether with monohydric alcohol, Ether of (b ₃ ) chain hydrocarbon diol and at least one aliphatic monohydric alcohol, Chain hydrocarbon tetracarboxylic acid having (c ₁ ) 4 carboxyl groups, hydroxy acid , alkoxy acid or oxo acid, at least one ester of an aliphatic monohydric alcohol, (c ₂₎ a chain hydrocarbon birds with 3 carboxyl groups Carboxylic acid, hydroxy acids, esters of alkoxy acids or oxoacids, and at least one aliphatic monohydric alcohol, (c ₃₎ a chain hydrocarbon dicarboxylic acids having two carboxyl groups, hydroxy acid, alkoxy acid or oxo An ester of an acid and at least one aliphatic monohydric alcohol, (d ₁ ) an ether of an aliphatic monohydric alcohol and an aliphatic monohydric alcohol, (d ₂ ) a dialkyl ketone, (d ₃ ) a fatty acid and an aliphatic 1 (E ₄ ) dialkyl carbonate, (e ₁ ) polyoxy C ₂ -C ₆ alkylene glycol, (e ₂ ) ester of polyoxy C ₂ -C ₆ alkylene glycol with at least one fatty acid, (e ₃ ) polyoxy C ₂ ~ C ₆ alkylene glycol and at least one aliphatic monohydric ether alcohols, (e ₄ Polyoxy C ₂ ~ C ₆ alkylene glycol, a chain hydrocarbon tetracarboxylic acid, esters of chain hydrocarbon tricarboxylic acid or chain hydrocarbon dicarboxylic acid,, (e ₅₎ polyoxy C ₂ ~ C ₆ alkylene glycol, 9. A chain hydrocarbon tetraol, a chain hydrocarbon triol, or an ether with a chain hydrocarbon diol, and (f ₁ ) a chain alkane, and any combination thereof, and selected from the group consisting of The absorbent article of any one of 11.

Images